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4Expression of neural adhesion molecules (NCAM) in healthy and
diseased renal tissue
Abstract
Introduction: Kidney performs essential physiological roles that include
metabolic waste excretion and maintenance of fluid and electrolyte balance. Different
factors may lead to renal dysfunction. Kidney diseases are currently a global public
health problem. Fortunately, dialysis and transplantation provide life-saving treatments,
but these therapies are rife with limitations. Thus, new ways of therapies, such as stem
cell treatment are more than required as an alternative and new glimmer of hope to all
nephrology patients. Neural cell adhesion molecule (NCAM) is widely expressed during
kidney development and it presents potential marker for renal stem/progenitor cells.
Aim: Aim of this dissertation was evaluation of NCAM presence in different
types of renal tissue (normal fetal or adult, and pathologically changed), and comparison
and correlation of NCAM expression with already defined stem cell markers in order to
more closely characterize renal fetal progenitor cells.
Method: Specifically designed primers were used for reverse transcriptase PCR,
after mRNA isolation from fetal, neonatal, adult normal, adult tissues with interstitial
fibrosis and tumor tissues, to clarify presence of different NCAM on nucleotide level.
Also, Western Blot tests were performed in order to identify expression of different
NCAM protein isoforms in healthy and kidney with disease. Further, FACS analysis
was done on renal cell lines to correlate NCAM expression with adult renal stem cell
markers CD24 and CD133. Co-expression and co-localization of NCAM with other cell
surface markers was also examined using immunohistochemistry and double
immunofluorescent staining.
Results: Our results showed aberrant NCAM expression in renal tumor tissues
as well as in tissue with interstitial fibrosis. Interestingly in both types of mentioned
tissues NCAM had co-expression with FGFR1, tyrosine kinase receptor, responsible for
cell proliferation and aggressive behavior in some epithelial tumors. Considering
NCAM expression on fetal samples possible renal progenitor population cell pool of
NCAM+CD24+ cells was found, which was not the case with NCAM+CD133+ cell pool.
Also, we had detected that NCAM molecules were post-trasnaltionally modified.
5Namely, all NCAM molecules become polysialylated after induction of mesenchymal
cells by ureteric bud tip and condensation of same mesenchymal cells. RT-PCR
analyses showed that all cell lines and tissues, except tumor tissues express all 3 major
NCAM isofirms NCAM-120, NCAM-140 and NCAM-180.
Conclusion: NCAM-120/140/180 isoforms are present in healthy and diseased
kidney tissues. Human fetal renal progenitors can be divided at least in two progenitor
cell populations: PSA-NCAM+CD24+CD326- population which will evolve to nephron
progenitors and NCAM+PSA-NCAM-CD24-CD326- cell pool which will probably
become stromal cells. Thus, polysialylation of NCAM could be a trigger of
mesenchymal-epithelial transformation during kidney development. In renal tissues
NCAM interacts with different molecules, such as FGFR1 or integrin α5β1, and this
interaction probably causes different cell signaling. Precise mechanism of
NCAM/FGFR1 interaction in tumors and exact role of NCAM in tumor development
are a matter of future investigations. But, since we had detected different localization of
NCAM/FGFR1 in tumor cells, expression of NCAM/FGFR1 in different cell
compartments could be activating various signaling pathways. NCAM+ renal interstitial
cells are significantly increased in the initial phase of renal interstitial fibrosis. They
display a morphological heterogeneity concerning co-expression of FGFR1, α5β1
integrin and other molecules relevant for renal interstitial fibrosis, and could be
responsible for the regulation of repairing process in renal tissue.
Key words: NCAM, PSA-NCAM, renal progenitors, fetal tissue, CD24, FGFR1,
integrin α5β1, RCC, interstitial fibrosis.
6Ekspresija neuralnih adhezionih molekula (NCAM) u zdravom i
obolelom bubrežnom tkivu
Rezime
UVOD: Bubreg ima značajnu fiziološku ulogu u izlučivanju štetnih produkata
metabolizma putem urina, kao i ulogu u održanju ravnoteže vode i elektorlita. Različiti
faktori mogu dovesti do poremećaja funkcije bubrega. Bolesti bubrega su trenutno
globalni problem javnog zdravlja. Dijaliza i transplantacija su trenutno dominantni
vidovi terapije koje se primenjuju u lečenju bubrežne isuficijencije, ali uz puno
ograničenja. Novi načini terapije, kao što je tretman matičnim ćelijama, su više nego
potrebni kao alternativa standardnim metodama lečenja i predstavljaju novi tračak nade
za sve pacijente koji imaju neki oblik bubrežne disfunkcije. Neuralni ćelijski adhezioni
molekul (NCAM) je široko ispoljen tokom razvoja bubrega i predstavlja potencijalni
marker renalnih stem/progenitorskih ćelija.
CILJ: Cilj ove disertacije je evaluacija NCAM ekspresije u različitim tipovima
bubrežnog tkiva (fetalno, adultno normalno i adultno tkivo sa intersticijskom fibrozom i
tumorsko tkivo), kao i njena korelacija sa ekspresijom već definisanih markera renalnih
stem ćelija kako bi se preciznije definisale fetalne renalne progenitorske ćelije.
METOD: Detekcija različitih NCAM izoformi na nivou nukleotida je vršena
primenom RT-PCR metode, nakon izolacije iRNK iz fetalnog i normalnog adultnog
tkiva, kao i tumorskog i tkiva sa intersticijskom fibrozom. Prisustvo NCAM isoformi na
proteinskom nivou, u pomenutim tkivima detektovano je upotrebom Western blot-a i
Imunoprecipitacije. Ko-ekspresija NCAM-a sa CD24 i CD133, markerima adultnih
renalnih progenitora ispitivana je upotrebom protočne citomertije (FACS) na renalnim
ćelijskim linijama. Imunohistohemijskim i dvostrukim imunofluorescentnim bojenjem
ispitivana je koekspresija i kolokalizaciji NCAM-a sa drugim ćelijskim markerima.
REZULTATI: RT-PCR rezultati ove doktorske disertacije su pokazale da sve
ćelijske linije i ispitivana tkiva, osim tumorskog tkiva eksprimiraju tri glavne NCAM
isoforme NCAM-120, NCAM-140 i NCAM-180. Takođe, detektovana je aberentna-
prekomerna NCAM ekspresija u tumorskom, kao i u tkivu sa intersticijskom fibrozom.
Interesantan nalaz čini pokazana koekspresija NCAM-a sa FGFR1, tirozin kinaznim
receptorom, koji ima ulogu u ćelijskoj proliferaciji i agresivnom ponašanju pojedinih
7epitelnih tumora. U ćelijama fetalnog tkiva bubrega uočena je koekspresija NCAM-a i
CD24. Koekspresija NCAM-a i CD133 nije uočena. Po prvi put smo dvostrukim
imunofluorescentnim bojenjem pokazali prisustvo post-translaciono modfiikovanih
polisijalinizovanih formi NCAM-a na ćelijama kondezovanog mezenhima u fetalnom
tkivu. Uporednom analizom koekspresije NCAM-a i PSA-NCAM, CD24 i CD326
među mezenhimalnim renalnim progenitorima u fetalnom tkivu mogu se izdvojiti bar
dve populacije progenitorskih ćelija: PSA-NCAM+CD24+CD326-, kao prekursori
budućeg nefrona, i NCAM+PSA-NCAM-CD24-CD326-, kao prekursori stromalnih
ćelija.
ZAKLJUČAK: NCAM-120, NCAM-140 i NCAM-180 izoforme su prisutne u
zdravom i obolelom tkivu bubrega. U fetalnom bubrežnom tkivu NCAM biva post-
translaciono modifikovan (PSA-NCAM). PSA-NCAM je prisutan na svim ćelijama koje
predstavljaju prekursore nefrona, sugerišući da je polisijalinizacija NCAM molekula
neophodna u toku mezenhimno-epitelne transfrmacije i procesa diferencijacije bubrega.
U tumorskom i tkivu sa intersticijskom fibrozom detektovana je koekspresija NCAM sa
FGFR1. Precizna uloga NCAM/FGFR1 interakcije u tumorima, ali i u tkivu sa
intersticijskom fibrozom još uvek nije definisana i predstavlja veliki izazov za buduća
istraživanja. Značajno povećanje NCAM+ ćelija u intersticijskoj fibrozi, kao i
koekspresija NCAM+ ćelija sa FGFR1 i integrinom α5β1 molekulima koji figuriraju u
ćelijskoj proliferaciji i signalizaciji, sugeriše da NCAM+ intersticijske ćelije mogu biti
od koristi prilikom regeneracije bubrega i kao takve imati primenu u budućoj ćelijskoj
terapiji bubrežne isuficijencije.
Ključne reči: NCAM, PSA-NCAM, renalni progenitori, fetalno tkivo, CD24, FGFR1,
integrin α5β1, RCC, intersticijska fibroza.
Naučna oblast: Molekularna medicina
Uza naučna oblast: Nefropatologija
UDK broj:
8Table of Contents
1. Introduction .................................................................................................................................... 1
1.1.Neural cell adhesion molecule (NCAM).................................................................................................. 2
1.2. NCAM and kidney development............................................................................................................. 5
1.3. NCAM in renal tumors............................................................................................................................ 8
1.4. NCAM in renal fibrosis............................................................................................................................9
1.5. NCAM in renal stem progenitors ...........................................................................................................10
2. Hypothesis/Aim............................................................................................................................. 12
3. Material and Methods .................................................................................................................. 13
3.1 Human renal tissue..................................................................................................................................13
3.1.1. Fetal tissue samples.........................................................................................................................13
3.1.2. Tumor tissue samples ......................................................................................................................13
3.1.3. Adult tissue samples ........................................................................................................................16
3.2. Cell lines.................................................................................................................................................17
3.3 Buffers and stock solutions .................................................................................................................19
3.4. Immunohistochemistry method..........................................................................................................22
3.5. Indirect Immunofluorescence method................................................................................................23
3.5.1. Double Immunofluorescence Staining (DIF) ..................................................................................23
3.5.2. Triple Biotin/Streptavidin Immunofluorescente method.................................................................24
3.6. Western Blot (WB).................................................................................................................................25
3.7. Immunoprecipitation (IP) ...................................................................................................................26
3.8. Flow cytometric analysis (FACS) ......................................................................................................28
3.9. RNA extraction...................................................................................................................................28
3.10. Reverse Transcriptase reaction.........................................................................................................29
3.11. RT-PCR amplification ......................................................................................................................30
3.12. Sequencing .......................................................................................................................................31
3.13. Assessment of NCAM+FGFR1+ cells in renal tumors ....................................................................32
3.14. Assessment of interstitial fibrosis (IF) and number of NCAM+ cells..............................................32
3.15. Statistical analysis ............................................................................................................................33
4. Results............................................................................................................................................ 34
4.1. Cell density in culture affect NCAM expression on HEK-293, CRL-1932 and TW33 cell
lines ...............................................................................................................................................................34
4.2. Localization of NCAM isoforms in fetal and neonatal tissue ................................................................42
94.2.1. NCAM+ CD326+ nephron progenitors...........................................................................................46
4.2.2. PSA-NCAM+ expression in nephron progenitors...........................................................................47
4.2.3. Co-expression of NCAM and PSA-NCAM with renal progenitor markers....................................49
4.2.4. Neonatal expression of renal progenitors........................................................................................53
4.2.5. DIF detection of NCAM co-localization with new mesenchymal antibodies.................................54
4.2.6. RT-PCR of NCAM isoforms in fetal, neonatal and adult kidneys ..................................................55
4.2.7. Expression of NCAM isoform specific proteins in fetal and neonatal kidney................................57
4.3. Co-expression of NCAM and FGFR1 in RCC.......................................................................................59
4.3.1. FGFR1/NCAM colocalization in RCC detected by double immunofluorescence..........................64
4.3.2. FGFR1 and NCAM expression in oncocytoma and other renal neoplasms....................................66
4.3.3. NCAM and Aquaporin 1 expression  in renal tumors .....................................................................66
4.3.4. Presence of NCAM 120, 140 and180 isoforms in renal neoplasms................................................68
4.4. NCAM+ cells in renal interstitial fibrosis ..........................................................................................69
4.4.1. Presence of NCAM isoforms in kidneys with and without fibrosis................................................70
4.4.2. Co-expression of NCAM+ renal interstitial cells and FGFR1, integrin α5β1 and
cadherin 9 ..................................................................................................................................................71
5. Discussion ...................................................................................................................................... 75
5.1. Discussion considering NCAM expression in fetal and neonatal tissues...............................................75
5.2. Discussion considering NCAM expression in renal tumors and cell lines.............................................81
5.3. Discussion considering adult tissue (normal and tissue with interstitial fibrosis)..................................88
6. Conclusion ..................................................................................................................................... 93
7. References...................................................................................................................................... 95
10
1. Introduction
The kidney has a major role in maintaining of human health, based on essential
physiological functions that include metabolic waste excretion and maintenance of fluid
and electrolyte balance. Different factors may affect renal function, whereby kidney
diseases can arise during development, juvenile, or adult life. Regardless of changes
related to congenital or sporadic diseases, tubuli and/or interstitium are frequently
damaged and their normal close mutual relationship could be replaced with an increase
in renal interstitial space, the progressive loss of peritubular vascularization and hypoxic
damage of the tubules, which further results in tubular atrophy. All these changes
mostly lead to interstitial fibrosis i.e. chronic renal failure. Also, cellular damage of the
functional units of kidney, known as nephrons, is a common attribute among diverse
kidney disorders. Progressive destruction of nephrons culminates in kidney failure.
Types of renal disease include acute kidney injury (AKI), which is the abrupt loss of
renal function that can often become permanent, and chronic kidney disease (CKD), the
progressive loss of renal function that culminates in organ failure known as end stage
renal disease (ESRD) (1,2). Kidney diseases are currently a global public health
problem. Fortunately, dialysis and transplantation provide life-saving treatments, but
these therapies are rife with limitations and place considerable burdens on patients, their
families and healthcare systems. Thus, it has become imperative to find alternative
ways, new therapies to treat existing kidney dysfunctions and to promote kidney health.
Regenerative medicine offers solutions by using stem cells as novel approach for
curing injured kidney. The presence of many renal cell types in kidney poses challenges
both to understanding and finding appropriate renal stem cells. Nevertheless, the
discovery of regenerative renal cells in adult kidneys, especially those in the nephron
tubule and PECs in the glomerulus, provides hope that there are already cell templates
and conducive environs where kidney integrity can be restored by promoting
regenerative mechanisms (2).
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1.1. Neural cell adhesion molecule (NCAM)
NCAM was originally described in 1974 as synaptic membrane glycoprotein D2 in the
brain (3), but as a cell adhesion molecule (CAM) it was presented for the first time in
1977 (4). NCAM was the first identified Ca-independent CAM of the immunoglobulin
superfamily which mediates homophilic and heterophilic binding to adjacent cells and
to the extracellular matrix by cis- and trans-interactions; and later recognized to be
expressed on the cell surface of almost all neural cell types in the central and peripheral
nervous system.
Thus, NCAM (also known as CD56) belongs to the immunoglobulin
superfamily (IgSF). Members of IgSF are group of glycoproteins (transmembrane and
membrane-anchored), that are characterized by presence of various number of Ig
modules. IgSF molecules are the most heterogeneous group of cell surface receptors,
with at least 65 proteins involved in cell adhesion (5). The extracellular part of IgSF
molecules contains multiple Ig-like modules connected like beads on a string. Ig-like
modules are usually followed by another bindings blocks, fibronectin type III (Fn3)
modules (6).
In humans, NCAM is encoded by a single-copy gene on band q23 chromosome
11. NCAM gene includes more than 314 kb and contains 19 major exons as well as 6
additional smaller exons. Alternative splicing of NCAM mRNA can result in 27
different NCAM isoforms (7, 8). Nevertheless, most studied are three major isoforms,
referred to as NCAM-120, NCAM-140 and NCAM -180 according to their different
molecular weights (8, 10). While the isoform NCAM-120 is anchored to the cell
membrane via a glycosyl-phosphatidyl-inositol (GPI) linker (11), both NCAM-180 and
NCAM-140 are transmembrane proteins with different lengths of their cytoplasmic
domains (C-terminus). On the other side, all NCAM isoforms have similar N-terminus,
which contain always 5 Ig-like modules and 2 Fn3 domains; in some soluble NCAM
isoforms it is possible to detect only one Fn3 domain (Scheme 1). Now it is known that
exons from 1-14 encode N-terminus (5 Ig-like and Fn3 domanis), while exons 17-19
encode intracellular region of NCAM molecules (Scheme 2) (12).
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Scheme 1. Graphic display of different isoforms of NCAM. EC- extracellular, TM-
transmemembrane, IC- intracellular, GPI- glycosylphosphatidylinositol anchor
Scheme 2. Graphic presentation of the NCAM gene; exons 1-19 which code 3 major
isoforms (12)
NCAM is abundantly expressed during embryonic development, whereas it is
found mainly in tissues of neural origin in the adult organism. In past, NCAM was
characterized as a mediator of cell-cell adhesion and cell adhesion as one of NCAM
function was firstly described. Today there are several models which present how
NCAM thru homophilic interaction regulates cell adhesion (Scheme 3). Several studies
demonstrated that interactions between NCAM Ig modules, (Ig1, Ig2, Ig3) resulted in
zipper like formations that are crucial for homophilic adhesion between two NCAM
molecules (13). In addition to cell-cell adhesion, homophilic interaction of NCAM
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induces signal transduction, resulting in neuronal differentiation (14, 15) and inhibition
of cell proliferation (16, 17). Also, NCAM plays a major role during development of the
nervous system, mediating adhesion between neural cells and stimulating neurite
outgrowth and asciculation (18-21).
Scheme 3. Schematic presentations of the cell–cell homophilic adhesion models,
(designed according to ref.13)
The extracellular and intracellular domain of NCAM can also mediate signaling
via heterophilic adhesion. In this type of interaction NCAM interplays with molecules
of extracellular matrix such as heparin/heparan sulfate (HSPGs), chondroitin sulfate
proteoglycans (CSPG) and different types of collagen (22-25). Also, NCAM mediates
signaling transduction through heterophilic dimerization of a broad range of other
molecules such as several heterophilic ligands: adhesion molecule L1, fibroblast growth
factor 1 (FGFR 1), the glial cell line-derived neurotrophic factor (GDNFR) (26-29).
Variable spectrum of different NCAM roles, as we have seen, is a consequence
of NCAM alternative splicing, and its homophilic and heterophilic interactions. But in
addition to that, NCAM can be also post-translationally modified by homopolymers of
α-2,8-linked N-acetylneuraminic acids (Neu5Ac or NANA), called polysialic acids
(polySia, PSA), that are bound at variable numbers to N-glycans on the extracellular
fifth immunoglobulin-like domain of the molecule (30). PSA changes of the
glycosylation patterns may convert different NCAM isoforms from interactive to anti-
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adhesive states (31). The PSA residues can extend beyond the NCAM protein core and
provide an enormous hydrodynamic exclusive space of the extracellular part of NCAM
that disrupts adhesive properties of NCAM and other interacting adhesive molecules
such as cadherins (32). Recent reviews have highlighted that PSA-NCAM is a critical
regulator of cell adhesion during neural cell differentiation and migration, neurite
outgrowth and correct synaptic targeting of growing axons for regular neuronal circuit
formation in the developing nervous system of the mouse embryo (33). In the adult
brain, PSA-free NCAM isoforms dominate, whereas PSA-NCAM has been shown to be
continuously expressed at sites of synaptic plasticity and neurogenesis. Thanks to all
these interactions and modifications NCAM is a crucial molecule in the developing as
well as in the adult human brain.
Also, now it is known that NCAM has various roles in other, non neural tissues.
Thus, NCAM is considered as specific marker in malignant lymphomas, neuroendocrine
carcinomas, Alzheimer’s dementia, myeloma and ovarian carcinomas (29, 34-39).
Recently it has been shown that in humans, NCAM express 3 major isoforms in healthy
adult non neural tissues such as: thymus, testis, pancreas, duodenum and kidney (12).
In kidney, NCAM is widely expressed during development (33), also on rare
interstitial cells in adults (40) and on renal tumors (41-44). Thus, in kidney NCAM has
a multiple role in mesenchymal-epithelial transformation, migration, proliferation and
epithelial-mesenchymal transformation, but the precise molecular signaling mechanisms
have not been established yet.
1.2. NCAM and kidney development
The kidney is one of the few organs that undergo mesenchymal-epithelial transition
(MET) during development. The metanephric (permanent) kidney develops from a
specialized region of the caudal end of the intermediate mesoderm called the
metanephrogenic mesenchyme. Reciprocal inductive cellular interactions between the
metanephric mesenchyme (MM) and the ureteric bud (UB) are considered to be
essential events in the development of metanephric kidney in mammals (45). Thus
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interplay between MM and cells at the tip of the branching UB thereby initiates MET of
specific multipotent renal progenitor cells (Scheme 4).
Scheme 4. Mesenchymal-epithelial transition as a result of interactions between MM
and UB
The human metanephros, in which renal stem/progenitor cells of the MM are
induced to form nephrons until birth, appears as early as at the 5th week of gestation
(wg). First, mesenchymal cells induced by cells at the tip of the outgrowing UB start to
condense, and form cap mesenchyme. Condensed mesenchymal cells induced by UB
start to polarize and form a pre-tubular aggregate (PA), a structure which is known to be
one of the first morphologically identifiable stages. Cells in PA continue to grow and
form a renal vesicle (RV, the most primitive stage of nephron development: a stage I
nephron). RV then elongates, becomes a comma-shaped (C) and then an S-shaped body
(S) (stage II nephron). Future growth divides S body to distal and proximal part. Distal
part of S body makes contact with and fuses with the distal component of the UB, and
latter forms the collecting duct. Proximal S body gives rise to capillary loop nephron
and Bowman’s capsule (stage III and IV). Soon afterwards, endothelial cells invade to
make a capillary knot-like outgrowth, the glomerular tuft, which goes on to form the
glomerulus (stage V). Together, the Bowman’s capsule and the glomerulus comprise the
definitive renal corpuscle. The rest of the nephron elongates to form components of the
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proximal tubule, the loop of Henle and the distal tubule (Scheme 5). The full
complement of glomeruli in the fetal human kidney is attained by 32-34 weeks (46-48).
Scheme 5. The development of the nephron, from I-V nephron stage (designed
according to www.gudmap.org)
Interestingly, un-induced as well as induced fetal renal MM cells, as well as
nephron progenitors (PA, RV, C and S body) are well known to widely express NCAM
(33, 49) as specific cell surface antigen up to the prenatal period during kidney
development in humans and rats. Induced mesenchymal cells are described to rapidly
loose expression of NCAM after MET on immature tubular cells during further
differentiation of the nephron (40, 50).
Kidney development, MM-UB interactions and consequent formation of the
nephron and the collecting system depend on genetic programs that are highly
regulated. Unique renal organogenesis as well as structural complexity of the adult
kidney (more than 26 mature cell types) has presented many challenges to the
identification and characterization of renal progenitor/stem cells.
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1.3. NCAM in renal tumors
Kidney cancers represent about 2% of all cancers in human population. The most
common form of renal neoplasms, with the highest mortality rate of the genitourinary
cancers in adults is renal cell carcinoma (RCC) (51). In recent decades, the incidence of
RCC has been steadily rising by 2-4% each year. In 2010, RCC was diagnosed in 90-
95% of all renal neoplasms (52).
RCC originates from tubular structures of the kidney and is classified into four
major histological types. Each type differs in origin, genetics, morphology and
behavior, metastatic potential and clinical outcome (52-55). Clear cell RCC (cRCC) is
the most common type, accounting for about 75-80% of all cases of RCC. Other types
are papillary (pRCC, 10-15%), chromophobe (chRCC 5%) and collecting duct (1%)
RCC; fifth group presents unclassified RCC (less than 2%). Characteristic of all
different RCCs is lack of early warning signs, frequent metastases, and resistance to
currently used treatments (54). The prognosis for patients with recurrent and/or
metastatic RCC is poor, median survival is 10-13 months and 5-year survival is < 5%
after nephrectomy (54-57).
Human RCCs seem to arise from a variety of specialized tubular-epithelial cells located
along the nephron; mainly cRCC, pRCC and chRCC originate from proximal and distal
tubules. These tubules originate from mesonephros after MET during kidney
development. Mesonephros strongly expresses NCAM, so re-expression of NCAM in
tumor cell of RCC could be expected. Re-expression of NCAM in RCC was first
described several years ago by Daniel et al (44). They showed that NCAM expression is
of interest for evaluating the prognosis of patients with cRCCs and for determining a
subgroup of patients at high risk for adrenal and CNS metastases. More recently, a study
on small group of RCC claimed that NCAM expression is present on RCC regardless to
histological type (58). Independent studies of NCAM and of FGFR revealed that both
molecules are involved in cell processes such as cell migration, proliferation, epithelial-
mesenchymal transformation (EMT), events that transform normal epithelial cell to
mesenchymal tumor cell. Also, recent data revealed that NCAM together with FGFR-1
promotes progression of ovarian carcinomas (59, 60).
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A better understanding of NCAM role in tumor molecular pathways that lead to
tumor appearance and growth may help in the development of new strategies for the
early detection and treatment of renal carcinoma.
1.4. NCAM in renal fibrosis
Kidney interstitial fibrosis (IF) can be defined as the accumulation of collagen and
related molecules in the renal interstitium. In normal adult kidney basal membranes of
the neighboring tubules are closely packed to each other, thus from the morphological
point of view renal interstitium in normal kidney represents a virtual space. So, if on
routinely stained slides for light microscopy renal interstitium could be seen, this
implies some pathological condition. EMT of tubular epithelial cells which are
transformed to mesenchymal fibroblasts migrating to adjacent interstitial parenchyma
constitutes the principal mechanism of renal fibrosis along with local and circulating
cells (61).
Normal human renal interstitium contains rare cells, mainly fibroblasts which
could be positive for vimentin or S100-A4 markers. Under normal conditions, the repair
process that follows the injury is completed by provisional ECM degradation and by
myofibroblast apoptosis, throughout mechanisms subjected to close control. However,
in some cases, after kidney damage, activated fibroblasts i.e. myofibroblasts express α
smooth muscle actin (αSMA) and then a repair mechanism dysregulation occurs;
sustained myofibroblasts play a major role in kidney fibrosis since they produce
extracellular matrix rich in collagen fibres, particularly collagen type I and III, that
coalesce forming fibrous bundles resistant to degradation (62).
In addition, other renal cells could contribute to interstitial fibrosis such as
transdifferentiated tubular (63) or endothelial cells (64) and vascular pericytes (65).
Interestingly, Markovic-Lipkovski et al had detected rare neural cell adhesion molecule
(NCAM) positive renal interstitial cells that seemed to be increased in incipient phase of
renal interstitial fibrosis (40). Considering different hypothesis regarding the origin of
interstitial cells in normal kidney, as well as in renal fibrosis (66), it is still a major
challenge to investigate molecular markers expressed by these interstitial cells. We
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therefore sought to examine co-expression of NCAM and several molecular markers
which are relevant for renal fibrosis like fibroblast growth factor receptor 1 (FGFR1),
integrin α5β1 and αSMA. FGFRs are a family of four tyrosine kinase receptors and can
be activated by their cognate ligands and by direct interaction with NCAM (67). FGFR1
plays multifunctional role in cell proliferation, migration and differentiation (68), and
might be involved in epithelial-mesenchymal transdifferentiation (EMT) and renal
fibrosis (69). Integrin α5β1 and fibronectin form a prototypic integrin–ligand pair which
is functionally very important because it mediates fibronectin fibrilar formation and
governs extracellular matrix assembly (70). Strong expression of α5β1 integrin has been
previously observed on interstitial cells in patients with IgA nephropathy, suggesting
that α5β1 integrin could interact with NCAM and may play a role in the pathogenesis of
chronic kidney disease in these patients (71).
1.5. NCAM in renal stem progenitors
Historically, kidney is widely regarded as an organ without regenerative powers, since
no new nephrons appear after 36 weeks of gestation in humans (33). Over the past two
decades, the phenomenon of renal regeneration has been increasingly investigated and
now it is currently speculated that the human kidney can regenerate in some contexts,
but the mechanisms of renal regeneration remain poorly understood. Today, numerous
groups of researchers re-evaluated problem of identification of multipotent renal
stem/progenitor cells. Characterization of renal progenitor cells is important step in
developing cell-based therapeutic applications for kidney disease. Two major
approaches, which are based on: a) identification of fetal human nephron progenitor
cells (hNPCs) or on b) discovery of a hierarchical population of adult renal progenitors
cells are currently in focus of investigations.
The fact that NCAM is widely expressed during fetal development and than
rapidly lost after birth, classified NCAM as marker for fetal renal stem cells (50). In the
human kidney, stem/progenitor cells are induced into the nephrogenic pathway to form
nephrons until the 34 week of gestation, and no equivalent cell types can be traced in
the adult kidney. (33). In the cited study (33), they proposed several different pools for
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renal progenitors. Thus, by FACS sorting in fetal kidney it is possible to found
FZD7+NCAM+EpCAM- nephron progenitors, characteristic for C and S body, than
NCAM+EpCAM- cell pool, possible stroma progenitors and NCAM-EpCAM+
cells,precursors for UB (33).
Studies that investigate adult renal progenitors and renal repair are increasing every
year. In contrary to fetal, adult renal progenitors does not express NCAM/EpCAM cell
populations. Nevertheless, adult renal progenitors within the Bowman’s capsule which
can generate novel podocytes and also proximal tubular cells have been identified (72).
This cell express CD24 and CD133 cell surface markers and treatment of acute renal
failure with CD24+CD133+ significantly ameliorated the morphologic and functional
kidney damage (73). Interestingly, in normal renal tissue a population of CD133+ stem
cells able to differentiate in vitro and in vivo into endothelial and epithelial cells (74).
Also, single NCAM+ interstitial cells present in fibrotic tissue may be possible adult
renal stem cells (40). Better understanding of renal stem cells, their behavior, origin and
their roles in kidney regeneration events, will contribute to create new clinical
treatments for kidney disease.
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2. Hypothesis/Aim
We expect that NCAM positive renal cells express specific progenitor markers such as
CD24, CD133, embryonic transcription factor Six2, GDNF molecule and marker
mezenhimalnh stem-cell W8B2, so that these cells may actually be potential renal
progenitor cells in the adult kidney and have role in the induction of interstitial fibrosis.
Aim
1. Characterization of the expression of NCAM isoforms in:
- Fetal kidney tissue
- Adult healthy kidney tissue
- Adult - renal tissue with initial interstitial fibrosis
- Renal cell carcinoma, and
- Renal - cell cultures
2. Identification and characterization new markers - antibodies to renal cells and tissues,
using a new monoclonal antibody W5C4C5, W8B2 - potential of mesenchymal markers
as well as potential new antibody for NCAM, W1C3 and 35C9 (obtained in the
laboratory of prof. Dr. JH Bühring, University of Tübingen), in order to differentiate
potential renal progenitor cells and clarification of NCAM role in the development of
kidney.
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3. Material and methods
3.1 Human renal tissue
Tissues analyzed in this thesis included different type of renal tissues such as fetal,
neonatal and adult samples. Adult samples were divided in: adult normal tissues
obtained from not transplanted kidney, adult normal tissues adjusted to tumor, renal
tumor tissues and adult tissues collected during routine biopsies. All tissue samples
were obtained after informed consent of the parents/patients and the study was approved
by the Ethic Committee of the Medical Faculty University of Belgrade (reference
number: 29/VI-7). All experiments in this thesis were done partly at the Center for
Medical Research, Eberhard Karls University Tübingen and at Institute of Pathology,
Medical Faculty, University of Belgrade.
3.1.1. Fetal tissue samples
Twenty one fetal kidneys from 15 to 30 weeks of gestation were obtained during
elective or spontaneously occurring abortions at Department of Obstetrics and
Gynecology, Medical Faculty of the University of Belgrade. Different kidneys: 15th,
20th, 22nd, 24th, 26th, 28th and 30th week of gestation were analyzed. Two samples of
neonatal renal tissue at 36th and 40th week of gestation provided from autopsies at the
Institute for Pathology, Medical Faculty of the University of Belgrade were also
investigated.
One piece of each sample was conserved in RNAlater (Qiagen Ltd., Germany), a
RNA stabilization reagent, for subsequent efficient RT-PCR analysis, the second part of
the tissue was put into cell culture medium RPMI 1640 (PAA Laboratories GmbH,
Austria) immediately after removal, snap-frozen, and stored in liquid nitrogen or at -
80ºC until further analysis, while third part of each sample was put in 4% buffered
formalin and embedded in paraffin for immunohistochemistry staining.
3.1.2. Tumor tissue samples
Renal tumor tissue was obtained from 49 patients (29 males, 20 females) undergoing
nephrectomy. Among these patients renal cell carcinoma was diagnosed in 36 cases,
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oncocitoma in 9 cases, 2 collecting duct carcinoma, one cortical fibroma and one
metanephric adenoma. Detailed clinical and pathological information was available for
all RCC cases, included histological subtypes, tumor size, nuclear grade (NG) and TNM
staging, listed in Table 1. For analyzed oncocitomas clinical features are present in
Table 2. The mean age of patients presented in Table 1 and Table 2 was 56.8 years
(range 34-87). All renal tumor samples were prepared and stored as it was previously
described in the section above (paragraph Fetal tissue samples).
Table 1. Summary of the clinicopathological features in RCC
Case no. Age Sex Tumor size (cm)# Nuclear Grade Stage
Clear cell RCC
1 61 F 6 1 pT2NxMx
2 39 M 3,5 1 pT2NxMx
3 58 M 4 1 pT1aNxMx
4 87 F 2,5 1 pT3aNxMx
5 71 M 5,5 1 pT3aNxMx
6 54 M 10 2 pT3bNoMx
7 64 M 9 2 pT3aNxMx
8 46 F 12 2 pT3aNxMx
9 58 M 6 3 pT1bNxMx
10 74 F 5 3 pT3aNxMx
11 44 M 7 3 pT1bNxMx
12 36 M 9 3 pT4N2M1
13 60 F 13,5 4 pT3aNoMx
14 75 F 8 4 pT3aNxMx
15 57 F 8 4 pT3N2Mx
16 64 M 8 4 pT3aNxMx
Multilocular cystic RCC
1 47 M 4 1 pT1aNxMx
2 34 M 4,5 1 pT1bNxMx
3 44 F 6 2 pT1bNxMx
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Papillary RCC
1 62 M 4,2 1, type I pT3aNxMx
2 59 M 3 1, type II pT3aNxMx
3 59 M 6 1, type II pT3NxMx
4 55 M 4,5 2, type II pT1bNxMx
5 59 M 3,5 2, type II pT1aNxMx
6 47 M 4 2, type II pT1aNxMx
7 59 M 3,5 2, type II pT1aNxMx
8 50 M 1,5 2, type II pT1aNxMx
9 55 M 4,5 3, type II pT3aNxMx
10 65 M NK 3, type I pT3bNxMx
11 56 M 10 3, type II pT3aNxMx
12 48 M 12 4, type II pT3aNxMx
Chromophobe RCC
1 43 M NK 1 NK
2 39 F 5 2 pT1bNxMx
3 60 M 2 2 pT1aNxMx
4 70 F 1,5 2 pT1aNxMx
5 61 M 7 2 pT1bNxMx
# - the biggest tumor diameter, NK- not known
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Table 2. Summary of the clinical and morphological features in oncocytoma
Case no. Age Sex Tumor size (cm)#
1 61 F 2,0
2 43 F 2,3
3 51 F 2,5
4 60 F 3,5
5 53 M 4,0
6 57 F 6,0
7 59 F 6,5
8 81 F 8,0
9 69 M 9,5
# - the biggest tumor diameter
3.1.3. Adult tissue samples
90 kidney biopsy specimens with various forms of glomerulonephritis and
glomerulopathies were analyzed in this thesis after the routine diagnostic workup was
completed. Paraffin-embedded samples were also further used for
immunohistochemistry. The second renal biopsy core was put into cell culture medium
RPMI 1640 (PAA Laboratories GmbH, Austria) immediately after removal, snap frozen
in liquid nitrogen and stored at -80ºC. In the cases where we had enough tissue, a piece
of tissue sample was conserved in RNAlater (Qiagen Ltd., Hilden, Germany), a RNA
stabilization reagent, for subsequent efficient reverse PCR (R-PCR) analysis.
Distribution of diagnosis among 90 analyzed biopsies was: lupus nephritis (LN)
- 24 cases, focal segmental glomerulosclerosis (FSGS) - 17 cases, membranous
glomerulonephritis (MGN) - 13 cases, membranoproliferative glomerulonephritis
(MPGN) - 8 cases, renal graft - 8 cases, IgA nephropathy - 6 cases,
mesangioproliferative glomerulonephritis (MesPGN) - 5 cases, rapidly progressive
glomerulonephritis (RPGN) – 5 cases, minimal change disease - 4 cases.
In addition normal tissue was also obtained from 10 cadaveric kidneys of young
healthy donors that were not transplanted and from 4 normal kidney samples adjusted to
tumor. These samples were also treated as it was described in section “Fetal tissue.”
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3.2. Cell lines
Two human epithelial adherent RCC cell lines were used for analysis of NCAM
expression in this thesis. One well characterized clear cell RCC (cRCC) line CRL-1932
(786-0) was obtained commercially from American Type Culture Collection (ATCC,
LGC Standards GmbH, Germany), while second cRCC cell line TW33 was established
in the laboratory of Professor Gerhard Müller (University of Göttingen, Germany).
Different NCAM antibodies tested on these cell lines are presented in Table 3.
Table 3. NCAM antibodies tested on cell lines.
Clone number Dilution Source Binding region Company/cat. no.*
Eric-1 1:75 Mouse mc N-terminus Ancell/208-020
NCAM-OB11 1:100 Mouse mc C-terminus Sigma/C9672
EP2567Y 1:150 Rabbit mc C-terminus Epitomics/2433-1
*cat.no.-catalog number
Also, embryonic epithelial adherent cell line HEK-293 (ATCC, LGC Standards GmbH,
Germany) was used to analyze NCAM expression and expression of other renal cell
progenitor markers listed in Table 4.
Table 4. Antibodies tested on cell lines.
Name Clone Dilution Source Company/cat.no
CD24 8.B.76 1:10 Mouse mc Santa Cruz/sc-58998
CD133/2 293C3 1:10 Mouse mc Miltenyi Biotec/130-090-851
FGFR1 M19B2 1:100 Mouse mc Abcam/ab823
PSA-NCAM 2-2B 1:250 Mouse mc AbCys S.A./AbC0019
EpCAM (CD326) 9C4 RTU# Mouse mc@ “Buehring Lab.”*
CD34 43A1 RTU Mouse mc “Buehring Lab.”
W1C3 W1C3 RTU Mouse mc “Buehring Lab.”
#
-ready to use supernatant, @-mouse monoclonal, *-kindly provided by Prof. H.J.
Buehring, Tuebingen
The retinoblastoma cell line Weri-Rb-1 was used as positive control (ATCC,
LGC Standards GmbH Germany). The cell lines were grown in culture in RPMI1640
27
medium (PAA Laboratories GmbH, Austria) supplemented with 10% fetal calf serum
and refobacin and cultivated at 37°C with 5% CO2.
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3.3 Buffers and stock solutions
Phosphate-buffered saline (PBS)
Reagent Amount to add (g)*
NaCl 8
KCl 0.2
Na2HPO4 1.44
KH2PO4 0.24
*- measures for preparation of 1x PBS
PBS can be made as a 1x solution or as a 10x stock. To prepare 1 l of either 1x PBS,
dissolve the reagents listed above in 800 ml of H2O. Adjust the pH to 7.4 with HCl, and
then add H2O to 1 l. Sterilize solution by autoclaving, store PBS on room temperature.
PBS/MgCl2
Reagent Amount to add (g)*
NaCl 8
KCl 0.2
Na2HPO4 1.44
KH2PO4 0.24
MgCl2•6H2O 0.10
*- Measures for preparation of 1L of 1x PBS/MgCl2
Sodium citrate buffer (10mM)
Reagent Amount to add
Trisodium citrate (dehydrate) 2.94 g
dH2O 1 L
Dissolve trisodium citrate in H2O and adjust the pH to 6.0 with 1 N HCl. Store at room
temperature for 3 or at 4°C for 6 months.
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Radio Immuno Precipitation Assay buffer (RIPA)
Reagent Amount to add
NP-40 (20%) 5 ml
Tris HCl 1M 5 ml
SDS (20%) 0.5 ml
NaCl 5M 30 ml
Na-deoxychlorate (10%) 5 ml
dH2O 50 ml
Tris-Buffered Saline (TBS) 10x
Reagent Amount to add
Tris base 5.6 g
Tris HCl 24 g
NaCl 88 g
dH2O 900 ml
Adjust the pH to 7.6 with HCl. For a 1X solution, mix 1 part of the 10X solution with 9
parts distilled water and pH to 7.6 again. The final molar concentrations of the 1X
solution are 20 mM Tris and 150 mM NaCl.
Tris-Buffered Saline, 0.1% Tween-20 (TBST)
Reagent Amount to add
TBS 10x 100 ml
dH2O 900 ml
Tween-20 1 ml
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FACS buffer
Reagent Amount to add
PBS 1x 500 ml
BSA (10%) 5 ml
Na azide (0.1%) 2.5 ml
Tris/Borate/EDTA Buffer (TBE) 10x
Reagent Amount to add
Tris base 108 g
Boric acid 55 g
EDTA 0.5M pH 8.0 40 ml
Dissolve Tris, Boric acid and EDTA in 800 ml dH2O and adjust the pH to 8.3 with HCl
and then add H2O to 1 l, autoclave for 20 min. For a 1X solution, mix 1 part of the 10X
solution with 9 parts distilled water. Store at room temperature.
2% Agarose gel
Reagent Amount to add
Agarose 2 g
TBE 1x 100 ml
GelRed Staining solution: (keep it in dark)
Reagent Amount to add
Gel Red 15µl
NaCl 1MBoric acid 5ml
dH2O 45 ml
Solution can be reused 3-4x, store it in dark.
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3.4. Immunohistochemistry method
Immunohistochemistry (IHC) staining was used for demonstrating the presence and
location of proteins in tissue sections. Fetal, adult and tumor samples were fixed in 4%
formalin and embedded in paraffin blocks. Before staining, steps 5 µm thick sections were
deparaffinized and dehydrated in xylene and declining series of alcohol (100%, 96%,
70% ethanol). Rehydrated slides were washed in distilled water and blocked for
endogenous peroxides with 3% H2O2. After blocking, slides were washed 3 times for 5
min in phosphate buffer saline (PBS). Next step in IHC method was heat-induced
antigen retrieval with sodium citrate 10 mM, pH 6.0 for 20 minutes in microwave. After
cooling for 20 min on room temperature (RT) and rinsing 3 times for 5 min in PBS
primary antibodies listed in Table 5 in proper concentration/dilution were applied on slides
and incubated for 1 hour on RT. Sections were then again washed 3 times for 5 min in
PBS. Further course of IHC staining was carried using EnVisionTM Detection System
(code K4007, K4009, DAKO, Germany) following staining procedure prescribed by the
manufacturer. In brief: HRP labeled anti-mouse or anti-rabbit polymer was incubated for
30 min. After washing, slides were treated with 3,3'-diaminobenzidine (DAB) or 3-
amino-9-ethylcarbazole (AEC) as substrate, for 2-10 min at RT and counterstained with
haematoxylin (code S3309, DAKO, Germany). Negative controls were performed by
omitting the first antibody. Specimens were mounted and coverslipped with aqueous-
based mounting medium Faramount (code S3025 DAKO, Germany) and non-aqueous
permanent mounting medium, Ultramount (code S1964, DAKO, Germany). The slides
were evaluated using the light microscope BX53 with DP12-CCD camera (Olympus,
Germany).
Table 5. List of antibodies used in immunohistochemistry staining
No. Name Clone Dilution Source Company/ Cat. no.
1 NCAM 123C3.D5 RTU Mouse mc Labvision/MS-204-R7
2 WT1 6F-H2 1:50 Mouse mc Dako/M3561
3 W1C3 W1C3 RTU Mouse mc “Buehring Lab.”
4 W5C4C5 W5C4C5 RTU Mouse mc “Buehring Lab.”
5 FGFR1 M19B2 1:100 Mouse mc Abcam/ab823
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6 TRA-1-60 TRA-1-60 1:50 Mouse mc Millipore/MAB4360
7 PSA-NCAM 2-2B 1:100 Mouse mc AbCys S.A./AbC0019
8 Cadherin 9 / 1:50 Rabbit pc* Sigma/HPA007167
9 CD34 43A1 RTU Mouse mc “Buehring Lab.”
10 CD326 9C4 RTU Mouse mc “Buehring Lab.”
11 CD133 293C3 1:10 Mouse mc Miltenyi Biotec/130-090-851
12 Aquaporin 1 1/22 1:50 Mouse mc Abcam/ab9566
*-polyclonal
3.5. Indirect Immunofluorescence method
3.5.1. Double Immunofluorescence Staining (DIF)
Five µm-thick cryostat sections were treated as it was previously described (75). In
brief, frozen sections cut from fetal, neonatal, adult and tumor renal tissue were dried
for 1h at RT, fixed in acetone for 10 min. at RT before use for indirect double
immunofluorescence labeling. After fixation, slides were incubated for 1h at RT with
rabbit monoclonal antibody against NCAM, clone EP2567Y (diluted 1:200), followed
by Cy3-conjugated goat anti-rabbit antibody (diluted 1:2000; Dianova). Then, the one
of the mouse monoclonal antibody listed in Table 6 in appropriated dilutions was added
followed by goat anti-mouse IgG-Alexa 488 (diluted 1:1000, Invitrogen). The cell
nuclei were identified by counterstaining with 4,6-diamino-2-phenylindolyl-
dihydrochloride (DAPI; 1 µg/ml Sigma-Aldrich, Germany). Negative controls were
performed in all experiments by omitting the first antibodies. In each staining
experiment cross-binding of the secondary fluorescence labeled antibodies was
controlled on specific control slides on which the first or second mAb was omitted.
Sections were mounted with Fluoro Preserve Reagent (Calboichem, Germany). All
slides were analyzed on epifluorescence microscopy with F-View-CCD camera
(Olympus, Germany), on an Axiophot Zeiss immunofluorescent microscope or on a
LSM 510 Confocal Microscope with Apotome (Carl Zeiss, Germany). Digital pictures
from every fluorescence channel were taken and superimposed for the specific antibody
staining, using the software AnalySIS from Soft Imaging Systems (Olympus, Germany)
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and the software AxioVision Release 4.8.2 version (Carl Zeiss, Germany) for analysis
and documentation. Fluorescence red signal represents NCAM expression, while green
signal corresponds to expression of one of antibodies listed in Table 6; yellow to orange
signal on merge revealed co-localization of two markers on the single cell.
Table 6. List of Primary mouse antibodies used in DIF staining with NCAM clone
EP2567YY
No. Name Clone Dilution Company/ Cat. no.
1 NCAM Eric-1 1:100 Ancell/208-020
2 CD24 8.B.76 1:50 Santa Cruz/sc-58998
3 CD133 293C3 1:10 Miltenyi Biotec/130-090-851
4 CD326/EpCAM 9C4 RTU “Buehring Lab.”
5 CD34 43A1 RTU “Buehring Lab.”
6 Ki-67 MIB-1 1:100 Dako/M7240
7 W1C3 W1C3 RTU “Buehring Lab.”
8 W5C4C5 W5C4C5 RTU “Buehring Lab.”
9 W8B2 W8B2 RTU “Buehring Lab.”
10 FGFR1 M19B2 1:100 Abcam/ab823
11 TRA-1-60 TRA-1-60 1:50 Millipore/MAB4360
12 Six-2 H-4 1:500 Santa Cruz/sc-377193
13 PSA-NCAM 2-2B 1:100 AbCys S.A./AbC0019
14 E-cadherin HECD-1 1:100 Takara/M106
15 Integrinα5β1 SAM-1 1:100 Chemicon/CBL497
16 Cdaherin 9 / 1:100 Sigma/HPA007167
17 Aquaporin 1 1/22 1:100 Abcam/ab9566
3.5.2. Triple Biotin/Streptavidin Immunofluorescente method
Fetal tissue samples were also stained using Biotin/Streptavidin immunofluorescence
technique. This staining protocol was used since both primary antibodies were produced
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in mouse. After fixation all slides were blocked 15 min. for Streptavidin
(Streptavidin/Biotin kit, Vector laboratories, UK), washed and then 15 min. blocked for
Biotin (Streptavidin/Biotin kit, Vector laboratories, UK) at RT. After blocking steps,
slides were incubated 1 h at RT with PSA-NCAM (diluted 1:400) or TRA-1-60 (1:50)
or E-cadherin (1:100). Next step was 30 min. incubation with goat anti-mouse-Biotin
(diluted 1:300, BA-9200, Vector laboratories, UK), followed by conjugated
Streptavidin-Alexa488 (diluted 1:500, Invitrogen, Germany) for 1h at RT. Then after
washing in PBS, slides were incubated over night with one of the previously mentioned
mouse mAb (CD24, CD133, CD34, Ki-67, EpCAM, E-cadherin, TRA-1-60) and next
day sections were treated with secondary antibody Cy3-conjugated goat anti-mouse
antibody (diluted 1:500; Dianova, Germany). Like in DIF method, the cell nuclei were
identified by counterstaining with 4,6-diamino-2-phenylindolyl-dihydrochloride (DAPI;
1 µg/ml, Sigma-Aldrich, Germany). Negative controls and cross-binding controls were
performed as it is described in DIF staining. Sections were mounted with Fluoro
Preserve Reagent (Calboichem, Germany). All slides were analyzed on an Axiophot
Zeiss immunofluorescent microscope or on a LSM 510 Confocal Microscope with
Apotome (Carl Zeiss, Germany) using the software AxioVision Release 4.8.2 version
(Carl Zeiss, Germany) for analysis and documentation.
3.6. Western Blot (WB)
Protein extracts from renal tissues were obtained by dissolving 50 x 20 µm thick frozen
tissue sections in 500 µl RIPA (Radio Immuno Precipitation Assay buffer) extraction
buffer (1% Triton-X100, 0,5 % sodium deoxycholate, 0,1 % sodium dodecyl sulphate,
150mM sodium chloride and 50mM Tris, EDTA 5mM, pH 8.0) for 60 min. on ice.
Protein extracts from cell lines were prepared using 1 x 107 cells per 1 ml RIPA buffer.
Afterwards the tissue and cell lysates were treated with ultrasound and centrifuged for
10 min. at 13000 rpm. Supernatants were harvested. Roti-Nanoquant protein
quantization assay (Carl Roth, Germany) as a modification of Bradford’s protein assay
was used to determinate protein concentration in samples. Assay was performed
according to manufacturer’s instructions. Concentration of each sample was determined;
samples were frozen at -80°C until further analysis. Samples containing equal amounts
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of proteins in lysates were separated on NuPAGE Novex SDS-PAGE 4-12 % Bis-Tris
Mini Gels (Invitrogen, USA). Sample preparation and run conditions were prescribed
by Invitrogen protocol. After electrophoresis, separated proteins were transferred into
0,45 mm PVDF (polyvinylidene difluoride) transfer membrane (Millipore, USA). Non-
specific protein binding sites were blocked with 5% milk solution in 1x Tris Buffer
Saline Tween 20 (TBST) for 1 h at RT. Thereafter the membranes were probed with
antibodies listed in Table 7 overnight and subsequently washed with 1x TBST for 15
min. Anti-Rabbit antibodies were detected by a goat anti-rabbit IgG antibody
conjugated with horseradish peroxidase (HPR), diluted 1:20000 (GeneTex, Inc, USA),
anti-mouse antibodies except PSA-NCAM were detected by rabbit anti-mouse IgG/HRP
diluted 1:8000 (Dako, Germany). PSA-NCAM antibody was detected with goat anti-
mouse IgM/HRP conjugated antibody dilution 1:10000 (Jackson ImmunoResearch,
USA). The immmunoreactive bands were visualized on high performance
chemiluminesence film (code, 28-9068-35 GH Healthcare Limited, UK), after the
membrane was incubated with RapidStep ECL Reagent (code 345818, Calbiochem,
USA).
Table 7. List of primary antibodies used for Western Blot
Name Clone Dilution Source Company/cat.no
NCAM EP2567Y 1:5000 Rabbit mc Epitomics/2433-1
NCAM Eric-1 1:100 Mouse mc Ancell/208-020
NCAM OB11 1:100 Mouse mc Sigma/C9672
PSA-NCAM 2-2B 1:1000 Mouse mc AbCys S.A./AbC0019
3.7. Immunoprecipitation (IP)
Fetal tissue lysates were tested for IP too. Sigma-Aldrich Protein A sepharose was used
as carrier-agarose affinity beads for precipitation of antibody-NCAM, clone EP2567Y
(1:100) and for antigen-containing sample-proteins in tissue lysate. Tissue lysates and
antibody samples were incubated 3 h at +4°C on MACS-mix, tube rotaror (Miltenyi
Biotec, Germany). After that, samples were centrifuged at 12000 g for 2 min. at +4°C.
Non-bound sample components are washed away in PBS-MgCa. Lysate-precleaning
supernatant and antibody pellet were incubated overnight at +4°C on MACS-mix. Next
day samples centrifuged at 12000 g for 2 min and pellet-precipitate was 3x washed in
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PBS-MgCa. Further precipitate was re-suspended in 20µl PBS-MgCa and run on
electrophoreses, prescribed by Invitrogen protocol, described above in Western blot
procedure. As primary antibody PSA-NCAM diluted 1:500 was used, and detected by
goat anti-mouse IgM/HRP conjugated antibody dilution 1:10000 (Jackson
ImmunoResearch, USA). The immmunoreactive bands were visualized as it is described
in Western blot.
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3.8. Flow cytometric analysis (FACS)
The adherent RCC and fetal cell lines were harvested by incubation for 2-3 minutes
with Trypsin (code T4424, Sigma-Aldrich, Germany). After blocking of non-specific
binding 10 min on 4°C with 10 mg/mL polyglobin (Gamunex 10%, Talecris
Biotherapeutics, USA), cells were incubated for 15 min, 4°C with 25 µL of proprietary
antibodies listed in Table 3 and Table 4. For combined indirect extracellular and
intracellular staining, cells were first labeled with non-conjugated antibody and then
stained with goat anti-mouse/anti-rabbit secondary antibody for 15 min. After
incubation time cells were washed twice in FACS buffer containing PBS supplemented
with 0.1 % bovine serum albumin and 2.5 ml of 0.1 % sodium azide and used for flow
cytometry. Cells labeled with proprietary mice antibodies were stained with 10 µl of
1:25 diluted F(ab’)2 fragment of R-phycoerythrin (PE) conjugated goat anti-mouse
antibody (code R0480, Dako, Germany), or with FITC-conjugated goat anti-mouse IgG,
dilution 1:200 (code 115-096-146, Dianova, Germany) as the secondary antibody. Cells
labeled with rabbit antibody were stained with 10 µl of 1:100 FITC-conjugated goat
anti-rabbit IgG (code 111-096-144, Dianova, Germany). Two washing steps were
performed before measuring the cells. As negative and positive controls, the mouse
monoclonal antibodies W6/32HK and W6/32HL respectively were used. The
extracellular and intracellular expression of NCAM and other stem cell markers was
assessed on cell lines by BD FACSVerseTM flow cytometry and FACSAria cell sorter
(Becton Dickinson, Germany). FACS files were analyzed using the available software
BD FACSDiva 6.1.3 (Becton Dickinson, Germany) or FlowJo (Milteny Biotec,
Germany).
3.9. RNA extraction
Total RNA extraction from cell lines and tissues was carried out using TRIzol (code
15596-018, Invitrogen, Germany) and RNeasy Mini Kit (code 74106, Qiagen, USA).
Amount of cells used for RNA extraction was 1 x 106, while tissue samples were
between 25-50 mg per sample. In each sample 1 ml of TRIzol was added, vortexed and
incubated with of 5 min at RT. After incubation, 200 µl chloroform (code 15593-31,
Invitrogen) was added and centrifuged 15 min on 12383 rpm on 4ºC. Liquid phase was
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carefully collected. Further steps were performed following the guidelines specified in
the RNeasy Mini Kit protocol. The concentrations of isolated RNA were measured on a
NanoDrop spectrophotometer (Thermo Scientific, USA). RNA samples were now
stored on – 70ºC until further analysis.
3.10. Reverse Transcriptase reaction
Isolated total RNA samples were transcript to cDNA using Super Script III First-Stand
Synthesis System (code 18080-051, Invitrogen, Germany). Amount of RNA sample pro
sample was 1 pg – 5 µg. All components were centrifuged before use and added in
specified volume for each sample:
Component Volume (µl)
RNA (till 5 µg) n
10 mM dNTP-mix 1
Oligo (dt)12-18(0,5 µg/µl) 1
DEPC-H20 (fill to 10 µl) n
End Volume 10
Samples were then incubated 5 minutes on 65°C. Denaturation was ensured putting
samples on ice for 60 seconds. cDNA synthesis mix (10 µl/pro sample) was added to
the samples after cooling and incubated on 50°C for 50 min.
cDNA Synthesis Mix:
Component Volume (µl)
10X RT buffer 2
25 mM MgCl2 4
0.1 M DTT 2
RNaseOUT™ (40 U/µL) 1
SuperScript® III RT (200 U/µL) 1
Termination of reaction was done by putting probes on 85°C for 5 min, then 1 min on
ice. To remove leftovers of RNA, samples were incubated with Rnase H (1 µl pro
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sample) for 20 minutes on 37°C. Until PCR amplification cDNA probes were stored on
80°C. In further PCR analysis we have used maximal 2 µl of cDNA pro reaction.
3.11. RT-PCR amplification
For specific amplification of NCAM-120,140 and 180 kDa mRNA the primers listed in
Table 8 were used. NCAM isoforms were analyzed in fetal, adult and tumor tissues. For
each amplification 500ng cDNA pro sample was used for PCR reaction. Amplification
was performed using Veriti® 96-Well Fast Thermal Cycler (Applied Biosystem, USA)
starting with an initial denaturation step at 94°C for 10 minutes and followed by 35 PCR
cycles, each of which consisted of denaturation at 94°C for 60 seconds, annealing at
55°C for 60 seconds, and extension at 72°C for 1 min and 30 seconds. The last cycle
was terminated by a final extension at 72°C for 10 minutes. A 316 bp fragment of Beta-
actin (Table 10) was also amplified by RT-PCR as the internal control.
Table 8. List of specific primers used for amplification of NCAM isoforms and β-actin
NCAM
Varian
t
Forward primer 5’ to3’ Reverse primer 5’ to3’
Product
Size
NCBI referent
sequence
NCAM
-120
GAACCTGATCAAGCAGG
ATGACGG
CTAACAGAGCAAAAGAAGA
GTC
321bp NM_0010766882.2
NCAM
-140
GTCCTGCTCCTGGTGGTT
GTG
CCTTCTCGGGCTCCGTCAGT 264bp NM_000615.5
NCAM
-180
CGAGGCTGCCTCCGTCAG
CACC
CCGGATCCATCATGCTTTGC
TCTC((REF)
336bp GenBank
AK056258.1
Β-
actin#
CCATCACGATGCCAGTGG
TA
TCAGAAGGATTCCTATGTG
GGC
316bp NM_007393.3
#  primers of ß-actin control amplification
AmpliTaq Gold DNA polymerase (250 Units, 5U/µl) with GeneAmp 10x PCR Gold
Buffer and MgCl2 solution (code 4311806, Applied Biosystems, USA) and GeneAmp®
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dNTP Blend/100 mM (code 4303443, Applied Biosystems, USA) were used for all PCR
reactions.
PCR mix for NCAM isororms pro sample:
Component Volume
cDNA 500 ng
10x PCR Gold 5 µl
25 mM MgCl2 4 µl
100 mM dNTP’s 0.8 µl
Gold Taq (2,5 U) 0.5 µl
Preimer F (10 pmol/µl) 1.5 µl
Preimer R (10 pmol/µl) 1.5 µl
Water (fill to 50 µl) /
Each amplification product was run for 30 minute on 80V and 80mA on a 2% agarose
(code A9539 Sigma Aldrich, Germany) and stained with GelRed (code 41003, Biotium,
USA) 30 min. in dark on RT to monitor for specificity on UV transilluminator.
3.12. Sequencing
DNA quantity of amplified NCAM RT-PCR products was checked by
BigDyeTerminator v1.1 cycle Sequencing Kit (code 4337450, Applied Biosystems,
USA). Cleanup of PCR products before sequencing was done using ExoSAP-IT (code
78201, Affymetrix, USA).
Sample preparation of cDNA for Sequencing:
Component Volume
cDNA 20 ng
2.5x RR* Premix 2 µl
5x BigDye SB** 1 µl
Primer F or R (3.2 pmol/µl) 0.32 µl
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Water (fill to 10 µl) /
*-Ready Reaction
**-Sequencing buffer
Cycle Sequencing was performed using Veriti® 96-Well Fast Thermal Cycler (Applied
Biosystem, USA) starting with an initial denaturation step at 96°C for 1 minute and
followed by 25 cycles, each of which consisted of denaturation at 96°C for 60 seconds,
annealing at 50°C for 5 seconds, and extension at 60°C for 4 min. The last cycle was
terminated by a rapid thermal ramp to 4°C and hold until ready to purify. Cleaning of
sequencing single DNA product was done in 96 well sequencing plate using
NaOAc/EDTA buffer (code S2080, Teknova, USA). After centrifuge on 1500 rpm for 5
seconds, samples were washed in 100% ethanol and centrifuged at 3000 rpm for 30 min,
and then 5 min with 80% ethanol again on 3000 rpm. Purified single-stranded DNA
products were sequenced using Sanger sequencing method and their compatibility was
compared with NCBI referent sequence for each NCAM isoform: NM_0010766882.2
for 120 kDa, NM_000615.5 for 140kDa and GenBank AK056258.1 for 180 kDa using
CodonCode Aligner software (Appendix 1).
3.13. Assessment of NCAM+FGFR1+ cells in renal tumors
Co-localization of FGFR1 and NCAM on the same tumor cell was assessed by number
of positive cells with respect to the total quantity of cells assessed by DAPI nuclear
staining, expressed on four-value discrete scale (scores 0, 1, 2 and 3):
0 - no FGFR1+/NCAM+ tumor cells;
1 - less than 30% FGFR1+/NCAM+ cells;
2 - 30 to 60% FGFR1+/NCAM+ cells;
3 - more than 60% FGFR1+/NCAM+ cells.
Co-localization was quantified by the consensus of two observers (J.M.L. and S.C.).
Fluorescence green signal represents FGFR1 expression and red signal NCAM
expression; while yellow to orange signal on merge revealed co-localization on the
single cell.
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3.1.4. Assessment of interstitial fibrosis (IF) and number of NCAM+ cells
Immunostaining for NCAM+ interstitial cells was evaluated, by light microscopy in a
blinded fashion, as a number of positive cells per field of view on the magnification
x400 in the region of fibrosis. Extension of IF in renal biopsy samples was semi-
quantitatively assessed applying a scale from 0 to 3 with 0 meaning no IF, 1 – less than
25% of renal tissue with IF, 2 - 25% to 50% of renal tissue with IF, and 3 - more than
50% of renal tissue with IF cells.
3.15. Statistical analysis
Statistical analysis was performed using the IBM SPSS software, version 20.0. After
applying Kruskall- Wallis test and Mann-Whitney test, P values <0.05 were considered
to be significant. Graphs were made using Microsoft Office Excel and R statistical
environment software packages.
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4. Results
4.1. Cell density in culture affect NCAM expression on HEK-293, CRL-1932 and
TW33 cell lines
Flow cytometry tests were done on fetal-tumor (HEK-293) and adult-tumor cell
lines (WT33 and CRL-1932). Weri-Rb1, retinoblastoma cell lines were used as positive
control for NCAM expression. FACS measuring was repeated on same cell types (3x
for each cell type) at different cell density. In the first round cells were prepared for
FACS when their density was between 40-50% of flask volume/surface, in the second
group measuring was done at cell density over 70%. Cell cultures of TW33 did not
show any diversity/difference in low or high density cell cultures groups, also in TW33
culture all live cells were grouped only in one population. Unlike to TW33, HEK-293
and CRL-1932 in high density culture had 2 separated populations (big and small) of
live cells.
On HEK-293 fetal cell line, in culture at low density (40-50%) and in bigger
population with high density NCAM/clone Eric-1 (16.8%), W1C3 (4.2%) (Figure 1A,
1B) and EpCAM (Figure 4A) were slight positive. Interestingly in HEK-293 cell culture
at high density (over 70%, in smaller population/pop2) expression of NCAM, clone
EP2567Y was distinctly stronger (23.33% of total cell population), while PSA-NCAM
showed weak positivity, 4.83% of total cell population (Figure 2), unlike in big
population and in low density culture PSA-NCAM was negative (Figure 5A). Green
signal on Fig. 2 represents tested cell surface markers: ep-180/EP2567Y, PSANCAM,
negative control with secondary antibody/FMO_R and positive control with antibody
W6/HL, while red signal represents unstained cells.
Fetal, HEK-293 cell lines were also tested for renal stem markers, such as:
CD24, CD133. Both stem cell markers were negative on HEK-293 cell line (Figure 3A,
3B).
Hematopoietic stem cell and endothelial cell marker CD34 (Figure 4B), as well
as tyrosine kinase receptor FGFR-1 (Figure 5B) was also analyzed on HEK-293 cell.
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Thus, in our results, after FACS measuring, HEK-293 live cells did not have expression
of CD34 or FGFR-1.
Unstained cells as negative control and cells stained only with secondary
antibody are presented in Figure 6.
Figure 1. Extracellular FACS analysis on HEK-293 cell line (40-50% density): A)
expression of NCAM/Eric-1 and B) W1C3.
B A
A
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Figure 2. Expression of NCAM, clone EP2567Y and PSA-NCAM in high density
population of HEK-293 cell lines.
Tumor cell lines, CRL-1932 had in culture with density over 70% two cell
populations, big and small. Expression of NCAM in big population was like in cell
culture with density 40 to 50%. Two different NCAM clones (Eric-1, EP2567Y, W1C3
as potential new clone for NCAM and PSA-NCAM were analyzed in CRL-1932. All
these markers in bigger populations were negative (Figure 7). While, in small
population expression of NCAM/EP2567Y was remarkably stronger 57.07% and other
markers (NCAM/Eric-1, W1C3 and PSA-NCAM) had weak expression around 2% of
total cells in small population (Figure 8, pop2).
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Figure 3. Extracellular FACS analysis on HEK-293 cell line (40-50% density):
expression of renal stem markers CD24 (A) and CD133 (B).
A
B
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Figure 4. Extracellular FACS analysis on HEK-293 cell line (40-50% density):
expression of EpCAM (A) and CD34 (B)
A
B
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Figure 5. Extracellular FACS analysis on HEK-293 cell line (40-50% density):
expression of PSA-NCAM (A) and FGFR-1 (B)
A
B
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Figure 6. Extracellular FACS analysis on HEK-293 cell line (40-50% density):
unstained cells (A) and secondary antibody control (B)
B
A
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Figure 7. Intracellular FACS analysis on CRL-1932 cell line in bigger population, cell
density over 70%
Figure 8. Intracellular FACS analysis on CRL-1932 cell line (cell density over 70%,
small population/ pop2)
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Nevertheless, TW33 tumor cell lines had one population in cases with density between
40-50% and in culture with density over 70%. In low density culture and in big
population of high density CRL-1932 cell culture abtybodies EP3567Y, Eric-1, W1C3
and PSA-NCAM were negative (data not shown). While in high density culture,
NCAM/EP3567Y had significantly stronger expression (44.46%) in comperation to
other tested maskers (Figure 9).
Figure 9. Intracellular FACS analysis on TW33 cell line (cell density over 70%)
To summarize: FACS analysis showed diffuse NCAM expression on cell lines. NCAM
EP2567Y was expressed in all tested cell lines (HEK-293, CRL-1932, TW33). Also
PSA-NCAM was present on all cell lines (2-4%). While new antibody W1C3 was
expressed only on HEK-293 cell lines. Stem cell markers: CD24 and CD133,
hematopoietic marker CD34 and tyrosine kinase receptor FGFR-1, were negative on all
analyzed cell cultures.
4.2. Localization of NCAM isoforms in fetal and neonatal tissue
Different clones of NCAM antibody, listed in Table 3, as well as new clone for
NCAM/W1C3 were tested on cryostat fetal samples by immunohistochemistry in order
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to make comparation between them and to distinguish which one is best for future
analyses. All 4 antibodies showed reactivity on all metanephric mesenchymal cells
between the branching ureteric tree of the inner zones of the developing kidney up to
the cortical nephrogenic area, where un-induced as well as condensed (CM) and cap
mesenchyme were stained. Beside the mesenchymal cells, presence of NCAM was seen
on epithelial cells, differentiated from the condensed mesenchyme into pre-tubular
aggregates (PA), renal vesicles (RV), comma- (C) and S- (S) shaped bodies within the
inner and outer nephrogenic zone. Indeed, NCAM, all tested clones: EP2567YY, OB-11
(C-terminus), as well as Eric-1 and W1C3 (N-terminus) was detected within
nephrogenic zone in all precursor structures of mature nephron (CM, PA, RV, C and S),
as well as in nephrogenic interstitium (NI) (Figure 10 A-D, Figure 11, Figure 12-red
photo). It looks like the tested antibodies recognized all NCAM isoforms, 120, 140 and
180 (Figure 11). Since no additional labeling could be observed, it implicates no
selective expression of the NCAM-120/-140/-180 by different cell populations within
the fetal kidneys.
WT1 as marker of undifferentiated renal stem cells progenitors was tested on
paraffin fetal samples (Figure 10E), and it showed presence in nephrogenic precursors,
start from RV, then C and S shaped body. Interestingly, weak WT1 positivity was
detected in some immature glomeruli (Figure 10E). Also, on same samples epithelial
markers, such as EpCAM (CD326) and cadherin 9 (CDH9) renal fibroblast markers
were analyzed. CD326 was present on epithelial cells of ureteric bud (UB), in
nephrogenic zone, as well as in nephron precursors: RV, C, and S and in Bowman’s
capsule and early tubuli (Figure 10F, Figure 12-green photo). CDH9 was completely
negative in nephrogenic zone, only positive signal was detected on the branching
ureteric tree and UB of the inner zones of the developing kidney (Figure 10G).
Hematopoietic marker CD34 in nephrogenic zone was present only in immature
glomeruli and single interstitial cells - precursors of future blood vessels (Figure 10H).
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Figure 10. Immunohistochemistry staining on cryostat and paraffin fetal samples in
nephrogenic zone: A) NCAM/EP2567Y, B) NCAM/Eric-1, C) NCAM/OB-11, D)
W1C3, E) WT1, F) EpCAM-CD326, G) CDH9 and H) CD34.
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Immunohistochemistry on all tested NCAM antibodies showed similar staining
pattern. Thus, in order to conform their compatibility, DIF staining was performed.
NCAM/EP2567Y as rabbit monoclonal Ab was combined with monoclonal NCAM Ab
(Eric-1, OB-11 and W1C3). NCAM clone EP2567Y had completely overlapped with
Eric-1, OB-11 and W1C3 on induced and un-induced mesenchimal cells (Figure 11).
Thus, it is possible that in fetal tissues all three major NCAM isoforms are present.
After these experiments NCAM/EP2567Y was used for all double staining with other
cell surface markers raised in mouse.
Figure 11. Double imunofluorescent staining on fetal samples conformed that analyzed
NCAM clones recognized same structures on fetal tissues.
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4.2.1. NCAM+ CD326+ nephron progenitors
To get better understanding of the functional significance of the three major NCAM
isoforms during nephron development, double IF was used to examine co-localization
of NCAM and other renal progenitor markers. Since NCAM was expressed on all
mesenchimal (un-induced and induced) cells in fetal tissues we considered NCAM+X+
cells as marker of early renal nephron progenitors. Thus, first we analyzed NCAM co-
expression with EpCAM (CD326). So, we detected co-localization of these 2 markers
on all epithelial nephron precursors. NCAM+CD326+ cells were detected on RV (v), C
and S body. NCAM+CD326- was mesenchimal cell in inner (NI) and outer nephrogenic
zone (Figure 12). In fetal tissue CD326 is also detected in Bowman’s capsule cells and
early tubular cells (Figure 12). In medulla of fetal kidney NCAM mesenchimal cells
around UB showed no overlapping with CD326, whereas epithelial cells of UB were
positive only for CD326 (Figure 12).
Figure 12. Expression of NCAM+ CD326+ nephron progenitors in nephrogenic zone
Furthermore, NCAM reactivity appeared to be progressively lost on epithelial cells of
the distal segment of the S-shaped body during nephron development, but remained on
the proximal part of S-shaped bodies. Thus, S body contains two populations NCAM+
CD326+ cells on proximal and medial part of S body, while distal part of the same S
body connected with UB had only NCAM- CD326+ cells (Figure 13).
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Figure 13. Expression of NCAM+CD326+ and NCAM-CD326+ cells in S-shaped body
NCAM expression in fetal kidney was also compared with Six2 gene specific as
undifferentiated mesenchymal renal progenitor. Results obtained by DIF staining
reveled co-localization of Six2 and NCAM in condensed mesenchzme (CM).
Figure 14. Co-localization of Six2 and NCAM on condensed mesenchzme in
nephrogenic zone
4.2.2. PSA-NCAM+ expression in nephron progenitors
As sialynated forms of NCAM could influence function of the molecule and were
imunoprecipitated from fetal tissues, localization of PSA-NCAM expression was
57
investigated in comparison with EpCAM (CD326) and NCAM. In fetal tissue PSA-
NCAM showed overlapping with EpCAM in RV, C and S shaped body (Figure 15).
This staining has also revealed that condensed and cap mesenchyme as well as in
pretubular aggregates were only PSA-NCAM positive, whereas EpCAM appeared on
RV and remained on S-shaped bodies. There was no differentiation between co-
expression of NCAM/EpCAM and PSA-NCAM/EpCAM (compare Figure 12 and
Figure 15).
Figure 15. Co-expression of PSA-NCAM and CD326 on nephron progenitors in
nephrogenic zone
PSA-NCAM was expressed more restrictedly compared to NCAM (Figure 16)
expression which was present on all mesenchymal cells including nephrogenic
interstitium (NI) and interstitial cells settled deeply in the cortex, corticomedullary zone
and medulla in addition to CM. Thus, PSA-NCAM was present exclusively in condense
mesenchyme and its derivates: PA, RV, C- and S-shaped body. Overlapping of PSA-
NCAM and NCAM was seen in condense mesenchyme and its derivates, while there
was no overlapping of PSA-NCAM and NCAM on interstitial mesenchymal cells
(Figure 16).
Figure 16. Co-expression of NCAM and PSA-NCAM in nephrogenic zone
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Interestingly Ki-67, a marker for cell proliferation, showed co-localization with PSA-
NCAM on cells of condensed mesenchyme (cm) as well as on PA (p), RV (v), C- and
S-shaped bodies within the nephrogenic zone (Figure 17).
Figure 17. Co-expression of proliferation marker Ki-67 with PSA-NCAM in
nephrogenic zone
4.2.3. Co-expression of NCAM and PSA-NCAM with renal progenitor markers
Further imunomorphological analyses were performed on NCAM and PSA-NCAM
cells with progenitor markers, such as CD24, CD133 and CD 34 also by DIF labeling.
The progenitor marker CD24 was seen to be co-expressed with NCAM in the outer
nephrogenic zone on the condensed and cap mesenchyme. Presence of both molecules
was seen on PA and all further stages of nephron development up to the S-shaped
bodies (Figure 16, NCAM-red photo, Figure 18, CD24- red photo). However, in
nephrogenic zone nephrogenic interstitium was positive for NCAM only, while CD24
was detected in UB tip, branch of UB and early tubules in medulla (Figure 18 - red
photo). Co-expression of PSA-NCAM and CD24 (Figure 18 - merged photo) is present
in PA, RV, C and S shaped body structures. Thus, the same structures of fetal kidney
starting with PA and up to S-shaped body co-expressed CD24, either with NCAM or
PSA-NCAM. Since the expression of PSA-NCAM was restricted, compared to NCAM
(Figure 16-green), consequently CD24 is expressed mainly in PSA-NCAM expressing
cells.
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Figure 18. Co-expression of PSA-NCAM and CD24 in nephrogenic zone
Distribution of NCAM, PSA-NCAM, CD24, CD133, CD326 and Ki-67 expression in
fetal renal tissue is given in Table 10.
Tabele 10. Results of double immunofluorescent staining on human fetal tissue
NCAM EpCAM PSA-NCAM CD24 CD133 Ki-67
metanephric
mesenchyme (mm)
+ - - - + -
nephrogenic
interstitium (ni)
+ - - - - -
cap mesenchyme (cm) + - + - - +
pretubular aggregate
(pa)
+ - + + - +
renal vesicle (rv) + + + + - +
comma shaped body
(c)
+ + + + - +
s-shaped body (s) + + + + - +
early tubuli (et) - + - - + +
bowmans capsule (bc) - + - + + -
loop of henle (lh) - + - - + -
distal tubuli (dt) - + - - + -
collecting duct (cd) - + - - + -
ureteric bud tip (ut) - + - + - +
ureteric bud (ub) - + - + - +
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To summarized: mesenchymal nephron progenitor cells in human fetal tissues at the
level of RV, C and S shaped body had expression of following cell surface markers:
NCAM, CD326, PSA-NCAM, CD24 and Ki-67. At these levels/stages of nephron
development only negative tested marker was CD133.
On the other hand, TRA-1-60, known as embryonic stem cell marker in analyzed fetal
tissue showed expression on the apical side of UB cells. Co-expression or co-
localization of TRA-1-60 and NCAM was not detected. Nevertheless, TRA-1-60
positive UB cells were also positive for CD24 (Figure 19A). Thus, CD24 was detected
on mesenchymal as well as on epithelial nephron progenitors.
E- cadherin (E-CDH), known as MET gene was also co-localized with TRA-1-60 on
UB cells (Figure 19B). Staining with E-CDH reveled that derivate of condensed
mesenchyme at level of RV (Figure 19B, green signal) start to expressed E-CDH. So,
like CD24, E-CDH is one more marker in fetal tissue which had been expressed on
mesenchymal and epithelial nephron progenitors.
Note:
Although it was specified in thesis application, results of co-expression of NCAM with GDNF
and 35C9 were not presented because of the technical problems. We were not able to get
appropriate GDNF antibody, all tested had huge background, and similar situation was with
aliquots of 35C9 antibody.
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Figure 19. Co-localization of TRA-1-60, CD24 and E-cadherin on epithelial renal
progenitors
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4.2.4. Neonatal expression of renal progenitors
In neonatal tissue, NCAM is detected on interstitial cells (Figure 20G), while epithelial
cells of some tubules remained slightly CD24 positive (Figure 20H). Thus, NCAM and
CD24 were expressed on different cell types, although they are closely localized in
same areas (Figure 20J).
Figure 20. Expression of NCAM and CD34 in neonatal tissue
Expression of CD133 was detected in glomeruli, Bowman’s capsule cells and on some
tubuli and no co-expression between CD133 and NCAM was detected (Figure 21A) in
fetal tissue. Some interstitial cells (deep in tissue) expressed CD133 and NCAM, but
they represent different cell population since co-expression of these molecules was not
observed (Figure 21B).
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Figure 21. Expression of CD133 and CD34 in neonatal tissues
CD34, known as a marker of hematopioetic stem cells and endothelial precursors was
also analyzed in DIF staining with NCAM. CD34/NCAM co-expression was detected in
rare cells of the newly formed immature fetal glomeruli as well as on single interstitial
cells of the nephrogenic interstitium. Interestingly CD34+ NCAM- cells were seen to be
present in vascular clefts of presumed late differentiation stages of the proximal part of
S-shaped bodies, which most likely could contribute to the capillaries of developing
glomeruli. (Figure 21C, D, E).
4.2.5. DIF detection of NCAM co-localization with new mesenchymal antibodies
New antibody W5C4C5 was testes by IHC on fetal and adult tissues. Analyses on adult
samples were negative, while expression of W5C4C5 in fetal tissues showed broad
expression of this marker on mesenchymal cells (Figure 22A). Co-localization with
NCAM was detected in all CM derivates and on non induced MM (Figure 22A). Very
interesting was detection of W5C4C5 on nerve and its co-localization in adult tissues,
(Figure 22B). On the other side, W8B2 expression was detected in some tubular
structures in fetal tissues (Figure 22B). No co-localization of W8B2 and NCAM were
found.
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Figure 22. Co-expression of new antibodies W5C4C5 (A, B) and W8B2 (C) with
NCAM in fetal tissues
4.2.6. RT-PCR of NCAM isoforms in fetal, neonatal and adult kidneys
The three major NCAM isoforms have been claimed to differ in their intracellular
binding to signaling molecules and in influences on the stability of cellular interactions.
To investigate the role of NCAM-120, -140, -180 in human kidney development, fetal
renal tissue samples obtained from 15 to 30 wg were analyzed by RT-PCR for the
expression of the specifically spliced NCAM mRNAs. Isoform specific RT-PCR
strategies were developed with specific primers, in exon 20 unique to NCAM-120
mRNA, at the boundary of exons 24/25 as well as in exon 18 for the detection of
NCAM-140 and NCAM-180 transcripts respectively. The specificity of the different
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NCAM RT-PCRs was verified by sequencing of the amplification products obtained
from the human retinoblastoma cell line Weri-RB1 which is known to express all major
isoforms (Appendix 1).
NCAM-120, -140 and -180 were detected in fetal samples from 20 to 30 weeks of
gestation (Figure 23A, line 1-6). Since equal amounts of mRNA per sample were used
for amplification of each isoform, our results suggest that NCAM-140 is dominant in all
analyzed fetal samples (Figure 23A, line 1-6). Different signal on agarose gel also
suggest that content of each isoform in the same sample is different and it varies from
sample to sample. In neonatal tissue all three isoforms were also detected (Figure 23A,
line 7). Signal for NCAM-140 was again the strongest, while NCAM-180 was barely
detectable (Figure 23A, line 7).
Figure 23. Detection of NCAM-120, -140, -180 in fetal, neonatal and adult tissues. A)
line 1- 20th wg, line 2- 22nd wg, line 3- 24th wg. Line 4- 26th wg, line 5- 28th wg, line 6-
30th wg.
For comparison, seven human adult kidneys were additionally analyzed (Figure 23B).
In these tissue samples, the same amounts of mRNA per sample were used for
amplification of each isoform. Tested tissues showed strong expression of NCAM-120
and -140 kDa isoforms in all analyzed cases (Figure 23B, line 1-7). The largest NCAM
isoform, NCAM-180 was clearly present only in 2 cases of adult tissues (Figure 23B,
line 3, 4).
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4.2.7. Expression of NCAM isoform specific proteins in fetal and neonatal kidney
Presence of different NCAM isoforms in fetal kidneys from the 22th to 28th wg and
neonatal kidney of 40 wg were also examined by WB and IP. The antibody EP2567Y
derived from an immunization with a synthetic peptide of the C-terminus of NCAM
which should recognized NCAM-180 was used in WB.
EP256Y however bound to NCAM-180 as well as a product of about 150 to 140 kDa
which could represent a shedded ectodomain fragment after proteolytic cleavage as it
has been observed previously. It could, however, not be excluded that the antibody also
recognized the 140kDa isoform. WB analyses with this antibody showed presence of
NCAM-140 in all fetal and neonatal tissues as shown in Figure 24A. EP256Y seemed to
also detect NCAM-180 as well as NCAM isoforms of higher molecular weight up to
250 kDa, suggesting reactivity with heavily polysialylated NCAM molecules (Figure
24A). Analysis of the same blots after stripping and exposure to the PSA-NCAM
specific antibody revealed a single broad band with an apparent molecular mass starting
at about 150kDa up to more than 250kDa in the fetal tissue samples of the 24th and 28th
wg and thus confirmed presence of PSA (Figure 24B). The weak single bands reacting
with PSA-NAM antibody were detected in fetal tissue of 22nd wg. In neonatal tissue of
40 wg PSA only a narrow band around 180 kDa was still visible on this blot (Figure
24B).
Since NCAM is not the only molecule who can be polysialilated with NANA in human
tissue immunoprecipitation of EP2567Y antibody and tissue lysates for 24th and 28th wg
was done. After precipitation analyzed fetal samples were “bloted” with PSA-NCAM.
Results of IP conformed that in renal fetal samples at 24th and 28th wg NCAM
molecules have been polysialilated (Figure 24C). Since equal amount of protein was
used for precipitation wider band on 24th wg suggest that earlier tissue samples had
stronger expression of PSA-NCAM.
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Figure 24. Western blot and immunoprecipitation verification of NCAM  and PSA-
NCAM expression. A) NCAM/EP2567Y expression in fetal and neonatal tissues; B)
PSA-NCAM expression in fetal and neonatal tissues; C) Immunoprecipitates of 24nd
and 28th wg by NCAM/EP2567Y blotted with PSA-NCAM; Negative controls – 24 neg
and 28 neg.
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4.3. Co-expression of NCAM and FGFR1 in RCC
Total number of RCC cases analyzed in our study was 36. From all analyzed RCC cases
30 (83.3 %) had expression of FGFR1, whereas the expression of NCAM was observed
in 26 (72.2 %) cases. Co-expression of FGFR1 and NCAM was detected in 26 (72.2 %)
cases. All NCAM positive cases were usually FGFR1 positive. Lack of both molecules
was found in 6 (16.6 %) cases. Immunohistochemistry showed that staining pattern
could be membranous and/or cytoplasmatic of NCAM and FGFR1, thus percentage of
positive cells with co-expression of both molecules was evaluated only by triple
immunofluorescent technique. In positive RCC cases expression of FGFR1 and NCAM
has been detected in the majority of tumor cells. Intensity of staining was variable from
case to case and it was not assessed.
Sixteen analyzed cRCC cases revealed FGFR1 expression in 14 (87.5 %) and NCAM
expression in 12 (75 %) cases. Co-expression was present in 12 (75 %) cases, since all
NCAM positive cases were also FGFR1 positive (Table 11). Interestingly, FGFR1 and
NCAM expression in cRCC with lower NG (I and II) was usually membranous and
uniformly spread on the cell surface (Figure 25A, 25B, 25E, 25F), while higher NG (III
and IV) had predominantly cytoplasmic in addition to membranous expression of these
markers (Figure 25C, 25D, 25G, 25H). Three cases of mcRCC were also studied. Only
one case of mcRCC had uniform membranous staining of FGFR1 and NCAM, whereas
the absence of FGFR1 and NCAM was noticed in 2 samples (Table 11).
Table 11. Summary of the clinicopathological features, FGFR1 and NCAM expression
in RCC
Case
no.
Age Sex
Tumor
size (cm)#
Nuclear
Grade
Stage FGFR1 NCAM
FGFR1/NCAM
co-expression
Clear cell RCC
1 61 F 6 1 pT2NxMx + - no
2 39 M 3,5 1 pT2NxMx + + yes
3 58 M 4 1 pT1aNxMx + + yes
4 87 F 2,5 1 pT3aNxMx - - no
5 71 M 5,5 1 pT3aNxMx + + yes
6 54 M 10 2 pT3bNoMx + + yes
7 64 M 9 2 pT3aNxMx + + yes
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8 46 F 12 2 pT3aNxMx - - no
9 58 M 6 3 pT1bNxMx + + yes
10 74 F 5 3 pT3aNxMx + + yes
11 44 M 7 3 pT1bNxMx + + yes
12 36 M 9 3 pT4N2M1 + - no
13 60 F 13,5 4 pT3aNoMx + + yes
14 75 F 8 4 pT3aNxMx + + yes
15 57 F 8 4 pT3N2Mx + + yes
16 64 M 8 4 pT3aNxMx + + yes
Multilocular cystic RCC
1 47 M 4 1 pT1aNxMx - - no
2 34 M 4,5 1 pT1bNxMx - - no
3 44 F 6 2 pT1bNxMx + + yes
Papillary RCC
1 62 M 4,2 1, type I pT3aNxMx + + yes
2 59 M 3 1, type II pT3aNxMx + + yes
3 59 M 6 1, type II pT3NxMx - - no
4 55 M 4,5 2, type II pT1bNxMx + + yes
5 59 M 3,5 2, type II pT1aNxMx + + yes
6 47 M 4 2, type II pT1aNxMx - - no
7 59 M 3,5 2, type II pT1aNxMx + + yes
8 50 M 1,5 2, type II pT1aNxMx + + yes
9 55 M 4,5 3, type II pT3aNxMx + + yes
10 65 M NK 3, type I pT3bNxMx + + yes
11 56 M 10 3, type II pT3aNxMx + + yes
12 48 M 12 4, type II pT3aNxMx + + yes
Chromophobe RCC
1 43 M NK 1 NK + - no
2 39 F 5 2 pT1bNxMx + - no
3 60 M 2 2 pT1aNxMx + + yes
4 70 F 1,5 2 pT1aNxMx + + yes
5 61 M 7 2 pT1bNxMx + + yes
# - the biggest tumor diameter, RCC- renal cell carcinoma, FGFR1- fibroblast growth factor receptor 1, NCAM-
neural cell adhesion molecule, NK – not known
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Figure 25. Co-expression of FGFR1 and NCAM in clear cell RCC. Lower NG had
exclusively membranous expression of FGFR1 (A, B) and NCAM (E, F). In contrast,
higher NG showed cytoplasmatic expression of FGFR1 (C, D) and NCAM (G, H) in
addition to membranous; magnification 400x. Abbreviations: NG-nuclear grade
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In 12 pRCC cases, 10 (83.3%) had co-expression of FGFR1 and NCAM. Two pRCC,
with NG I and II lacked both molecules (Table 11). In contrast to cRCC, expression of
FGFR1 and NCAM in pRCC appeared to be mainly cytoplasmatic regardless to NG
(Figure 26).
Figure 26. Co-expression of FGFR1 and NCAM in papillary RCC. FGFR1 (A-C) and
NCAM (D-F) showed dominant cytoplasmatic expression in addition to membranous in
all nuclear grades; magnification 400x.
All 5 chRCC cases expressed FGFR1, while weak NCAM expression was observed in 3
cases (Figure 27A, 27B) with predominantly cytoplasmatic staining.
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Figure 27. Immunohistochemistry and immunofluorescent staining pattern in
chromophobe RCC and in oncocytoma. Chromophobe RCC showed mainly
cytoplasmatic and membranous FGFR1 expression (A), while NCAM (B) had weak
predominantly cytoplasmatic pattern in these RCC. In oncocytoma both methods
revealed clearly cytoplasmatic expression of FGFR1 (C, E) and NCAM (D, F). Co-
localization of FGFR1 and NCAM in oncocytoma, yellow to orange merge, G.
Magnification 400x, cell nuclei blue, stained with DAPI.
73
Statistical analysis of the data obtained by immunohistochemistry showed that co-
expression of FGFR1 and NCAM in RCC was present regardless of histological type
and all other clinicopathological data listed in Table 11 (p<0,05).
4.3.1. FGFR1/NCAM co-localization in RCC detected by double
immunofluorescence
Results obtained by triple immunofluorescent staining clearly showed co-localization of
FGFR1 and NCAM, i.e. expression of both markers on single renal tumor cell (Figure
28, merged photos). By triple immunofluorescent technique, NCAM positive cells
better corresponded to FGFR1 positive cells in comparison to immunohistochemical
staining where FGFR1 was usually stronger than NCAM (compare Figures 25-27 to
Figure 28). Using this technique, it was much easier to see that cancer cells of RCC with
higher NG, in addition to cytoplasmatic, had aggregated membranous FGFR/NCAM co-
localization (Figure 28I, 28L, 28O, white arrows). The semi-quantitative approach
showed that number of FGFR1+/NCAM+ RCC cells was increasing with nuclear grade
in cRCC and pRCC, since the majority of cases with lower NG (I-II) had co-localization
score 0-2 (Figure 28, A-F), while in high NG RCC (III-IV) co-localization score was 3,
meaning that more than 60% of tumor cells had FGFR1 and NCAM expressed on the
same tumor cell (Figure 28, G-O).
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Figure 28. Co-localization of FGFR1 and NCAM in clear cell and papillary RCC.
Lower NG tumors (I-II) had co-localization score between 0 and 2 (Figure 4C, 4F). In
tumors with higher NG (III-IV) co-localization score was 3 (I, L, O).
Legend: cRCC - clear cell RCC, pRCC - papillary RCC, NG - nuclear grade, green -
FGFR1, red - NCAM, yellow to orange - merge of FGFR1 and NCAM, blue - nuclei
stained with DAPI.
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4.3.2. FGFR1 and NCAM expression in oncocytoma and other renal neoplasms
Both techniques - immunohistochemisry (Figure 27C, 27D) and immunofluorescence
(Figure 27G-J) - clearly revealed exclusive cytoplasmatic expression of FGFR1 and
NCAM in 9 oncocytoma cases (Table 12).
Table 12. Summary of the clinicopathological features, FGFR1 and NCAM expression
in oncocytoma
Case
no.
Age Sex Tumor
size
(cm)#
FGFR1
cytoplasmatic
NCAM
cytoplasmatic
FGFR1/NCAM
co-expression
1 61 F 2,0 + + Yes
2 43 F 2,3 + + Yes
3 51 F 2,5 + + Yes
4 60 F 3,5 + + Yes
5 53 M 4,0 + + Yes
6 57 F 6,0 + + Yes
7 59 F 6,5 + + Yes
8 81 F 8,0 + + Yes
9 69 M 9,5 + + Yes
# - the biggest tumor diameter, FGFR1- fibroblast growth factor receptor 1, NCAM- neural cell adhesion molecule
Absence of FGFR1 and NCAM expression was found in one case of cortical fibroma
and in two samples of collecting duct carcinoma, while the single case of metanephric
adenoma showed expression of FGFR1 and NCAM.
4.3.3. NCAM and Aquaporin1 expression in renal tumors
Aberrant NCAM expression in all RCC types and in oncocytoma was compared to
Aquaporin 1 (AQP1). AQP1 expression was characteristic only for mature proximal
tubuli.
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Figure 29. Expression of NCAM and AQP1 in clear cell and papillary RCC. A) Only
rare cells in cRCC showed NCAM+AQP1+ cells (white arrow). B) Interestingly in
pRCC cells co-localization of NCAM and AQP1 was not detected.
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Ontogeny of cRCC and pRCC origin indicated that these two RCC types arise from
proximal tubuli. Thus, it was not surprising results that AQP1 was detected on cRCC
and pRCC (Figure 29), but not in chRCC, collecting duct carcinoma and oncocytoma.
Interestingly were findings by DIF staining, which showed that only few
NCAM+AQP1+ cells in cRCC (Figure 29A, white arrow), in this type tumor cells
mainly express one of analyzed markers (Figure 29A). On the other hand, in pRCC
NCAM+AQP1+ cells were not found. Tumor cells in pRCC express NCAM or AQP1
(Figure 29B).
4.3.4. Presence of NCAM 120, 140 and180 isoforms in renal neoplasms
Five different tumor types, which had FGFR1 and NCAM expression by
immunomorphology, were studied for NCAM 120 and 140 mRNA. All analyzed RCC
cases: cRCC, pRCC, chRCC, as well as two benign tumors, oncocytoma and
metanephric adenoma, revealed presence of NCAM 140 (Figure 30A). NCAM 120 was
present only in chRCC and in both benign renal neoplasms (Figure 30B). Two RCC
cases, cRCC and pRCC, were negative for NCAM 120.
Figure 30. RT-PCR expression of NCAM 140 (A) and 120 (B) isoforms in various renal
neoplasms.
Legend: line 1 - metanephric adenoma, line 2 - oncocytoma, line 3 – chromophobe
RCC, line 4 – papillary RCC, line 5 – clear cell RCC.
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4.4. NCAM+ cells in renal interstitial fibrosis
Renal interstitial NCAM+ cells were rarely present in tubulointerstitial compartment of
human non-transplanted kidney obtained by cadaveric donors, used as a control group.
Analysis of the 90 kidney paraffin embedded biopsy specimens showed increased
number of NCAM+ interstitial cells in 41 cases (45.6%). The distribution of NCAM+
interstitial cells among different forms of glomerulonephritis and glomerulopathies is
showed in Figure 31: NCAM+ cells were increased in 66.7% LN, 53.8% FSGS, 53.8%
MGN, 12.5% MPGN, 40% RPGN, 40% MesPGN, 16.7% IgA nephropathy, 25% of
renal grafts.
Figure 31. Distribution of NCAM+ interstitial cells among various renal diseases
Statistically significant increase of NCAM positive renal interstitial cells was present
mainly in incipient interstitial fibrosis, assessed as scale 1, compared to all others scales
of fibrosis (p<0.001), showed in Figure 32.
Figire 32. Number of NCAM+ renal interstitial cells in different stages of interstitial
fibrosis
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4.4.1. Presence of NCAM isoforms in kidneys with and without fibrosis
Thirteen renal biopsies samples were analyzed using specific primers for all the three
NCAM isoforms, (Figure 33a, 34b and 34d). RT-PCR were done on eight control renal
tissues and three cases with interstitial fibrosis (Figure 33a: line IV, VIII and X). Line X
belongs to case which represents lupus nephritis with diffuse incipient interstitial
fibrosis since no tubular atrophy is present (Figure 33b), with increased number of
NCAM positive cells, shown in Figure 33c.
Figure 33. RT-PCR: 3 NCAM isoforms in different renal biopsies samples.
In addition, two more cases with significant increase of NCAM expression were
analyzed for 3 different NCAM isoforms: first, FSGS with focal incipient fibrosis
(Figure 34a) and results of RT-PCR (Figure 34b), and second, MPGN with incipient
fibrosis (Figure 34c) and results of RT-PCR (Figure 34d).
Unfortunately we did not find any difference between presence of NCAM
isoforms (120, 140 and 180) in kidneys with and without interstitial fibrosis, with the
exception of one sample with diffuse interstitial fibrosis where PCR band of NCAM180
was absent (Figure 33a: line X; Figure 33b and 33c).
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Figure 34. Detection on NCAM 120, 140 and 180 in FSGS and MPGN
4.4.2. Co-expression of NCAM+ renal interstitial cells and FGFR1 integrin α5β1
and cadherin 9
Using immunoperoxidase staining we revealed presence of few relevant markers for
fibrosis on renal interstitial cells, such as FGFR1 (Figure 35a) and α5β1 integrin (Figure
35b) and cadherin 9 (CDH9, Figure 35c, red star). Therefore, further analysis using
double immunofluorescence staining was applied to clarify whether NCAM+ renal
interstitial cells could co-express these markers in normal renal tissue and in kidneys
with fibrosis.
Figure 35. Expression of FGFR1, integrin α5β1 and CDH9 on interstitial cells. Red star-
rare CDH9 cell in initial interstitial fibrosis
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Double immunofluorescence technique of normal control tissue samples revealed that
rare NCAM+ renal interstitial cells could co-express FGFR1 (Figure 36A), or α5β1
integrin (Figure 36B). However, there was great heterogeneity between NCAM+ renal
interstitial cells, since not all NCAM+ cells co-expressed these molecules.
Figure 36. Co-localization of NCAM with FGFR1 and α5β1 integrin on same interstitial
cell
Furthermore, we showed that increased NCAM+ renal interstitial cells in incipient
fibrosis, could also co-express FGFR1, or α5β1 integrin (Figure 37). There was a great
variability between co-expression of these three markers and NCAM on renal interstitial
cells from case to case associated with fibrosis. For instance, in some cases with initial
phase of fibrosis, rare NCAM+/FGFR1+ renal interstitial cells were detected like in
control tissue. In contrast, other renal biopsy specimens with incipient fibrosis almost all
NCAM+ renal cells co-expressed FGFR1 (Figure 37, a1-a3). In the renal tissue with
fibrosis, increased number of cells coexpressing NCAM and α5β1 integrin (Figure 37,
b1-b3) in comparison to normal tissue was observed.
82
Figure 37. Co-expression of NCAM with FGFR1 and α5β1 integrin in interstitial
fibrosis
In addition, in some cases of initial interstitial fibrosis we detected rare NCAM+CDH9+
interstitial cells (Figure 38A, white stars). Very interesting was also founding PSA-
NCAM+ NCAM+ cells in tissue with fibrosis (Figure 38B), having in mind that PSA-
NCAM was detected only in fetal renal tissues. Also new mesenchymal marker W8B2
was expressed and co-localized with NCAM on rare interstitial cells (Figure 38C, white
arrow).
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Figure 38. Co-expression of NCAM with rare CDH9+, PSA-NCAM+ and W8B2+ cells
in initial interstitial fibrosis.
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5. Discussion
5.1. Discussion considering NCAM expression in fetal and neonatal tissues
Significance of NCAM expression on renal progenitor cells in correlation to adult renal
stem markers: CD24, CD133 on the same progenitor cells was investigated in fetal and
in neonatal tissue. PSA-NCAM co-expression with NCAM and other cell surface
markers known to be present on renal fetal and adult progenitor (CD24, CD133) cells
was also evaluated. Since NCAM is not expressed on UB or differentiated epithelia, it is
likely to be used for the identification of metanephric mesenchyme-derived progenitor
nephron populations (NCAM+X+) if the second marker is clearly not detected on MM
and stromal cells. This definition is most suitable for the NCAM+CD326+ fraction
among the human fetal kidney cells (33).
Using special designed primers for each NCAM isoform, our RT-PCR analysis
on fetal, neonatal and adult kidney tissue shows presence of all three isoforms in the
fetal as well as in the adult tissue, indicating that there is no evidence of a one specific
embryonic NCAM isoform in kidney. Similar results was also detected on mouse
embryonic kidney, hrere immunobloting analyses showed presents of 3 distinct bands
on 120, 140 and 180 kDa, unlike to embryonic spinal cord were broad band from 170-
250 kDa was detected (50). Our results correspond also to a previous study done by
Gattenloehner et al (12). Present molecular genetics evidence of the predominant
NCAM isoforms 120 kDa, 140 kDa, and 180 kDa present in humans was also
corresponding with our immunofluorescent results. Namely, immunohistochemistry and
double immunofluorescent analysis with NCAM antibodies like Eric-1 and W1C3
which recognize N-terminal domain of NCAM, common to all isoforms, as well as
OB11 and EP2567Y which recognised C- terminus, had strong and similar expression
pattern on MM cells (Figure 10A-D, Figure 11). Although lack of NCAM-180
expression in the neonatal sample, less intensive expression of NCAM-180 in adult
tissue in comparison to the expression of NCAM-120/140 in the same samples and clear
expression of NCAM-180 in all tested fetal tissues, may suggest that 180 kDa isoform is
a predominant NCAM isoform during renal development.
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Immunohistochemistry staining of NCAM, WT1 and CD326 showed that co-
expression of these 3 molecules on nephron progenitors could be detected at level of
RV, C and S shaped body (Figure 10E-F). New studies indicated that WT1 is necessary
for FGF signalling in renal progenitor and cell surviving (76). In contrast, co-expression
of NCAM with CD34 and CDH9 was not observed. CD34 positive cells were localized
peri-tubular mainly on endothelial cells, while CDH9 was expressed exclusively in UB
cells in fetal tissues. This result is very interesting taking into account that CDH9 was
known as marker of renal fibroblast (77) Nevertheless, since in fetal tissue CDH9 was
restricted to UB it could be considered as UB marker in fetal epithelial renal
progenitors.
In neural development it has been shown that mainly NCAM-140 and 180 kDa
modulate cell migration and neuron growth; NCAM-180 is found in postsynaptic
densities of mature neurons (78), while NCAM-140 is expressed in growth cones and
axon shafts of developing neurons (79) and that NCAM-120 expression is primarily in
glia (80). However, all NCAM isoforms may support synaptogenesis (81). Looking
back on immunomorphological profile un-polysialylated NCAM molecules in fetal
tissues are present on MM cells in renal stromal-future components of renal medulla in
adult kidney, according to our results and previous studies (33, 50). These MM cells,
which surround UB tree and follow its growth, and which are not induced by UB tip did
not show any co-expression of NCAM with any other self surface progenitor markers:
CD24, CD133, CD34, Ki-67 and did not had polysialylation of NCAM. Indicating these
facts, it can be suggested that NCAM+ renal mesenchymal progenitor cells which
“escort” UB have the same purpose in fetal kidneys as in neural development,
suggesting that NCAM molecules are responsible for cell migration in this stage of
kidney development.
Results on fetal cell lines HEK-293, showed that cell lines with density over
70% expressed NCAM (23.33%). Interestingly, low density cell cultures had almost 2
times less NCAM expression (16.8%). High density cultures had two populations of
cells, and in these cases bigger population had similar NCAM expression like cells in
low density culture. These finding showed that HEK-293 line had diffuse NCAM
expression which was in correlation with growing conditions, indicating that NCAM
cell to cell assembling was present only when cells are “overcrowded”. On the other
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hand, expression of CD24, CD133, CD34 and FGFR1 were negative in both tested
group, while CD326 shored low positive signal (2.1%). These results are contrary to
observation of Metsuyanim et al on human fetal kidney cell lines (HFK), which showed
over 30% of NCAM+ cells and strong expression of CD326, CD24 and CD133 (over
60%), while CD34 was >15% (33). Thus, HEK-293 cell line was not good “model
culture” for investigation of NCAM and renal progenitors in kidney. In addition
recently findings of the same group of investigator showed that HFK cell cultured in
serum free medium (SFM) had lower NCAM expression (5-20%), these SFM cells were
able to form compact colonies of small round/cuboidal cells, while HFK in serum
containing medium yield dispread fibroblast shaped cells (82).
FACS analysis of renal fetal progenitor surface markers demonstrated two
different progenitor pools in the nephrogenic zone of fetal tissue: NCAM+EpCAM- pool
of mesenchymal cells and NCAM-EpCAM+ pool of epithelial cells in UB (33). Using
DIF staining, we tried to further determinate localization of these cells. Our results show
that NCAM+EpCAM- cells are first expressed in CM. Further differentiation and
localization shows that NCAM molecules on NCAM+EpCAM- cells became
polysialylated in CM. PSA-NCAM+EpCAM- cells simultaneously with polysialylation
start to express CD24. So we could say that in nephrogenic zone NCAM+ cells which
have been induced by UB tip, have “new” renal progenitor pool of PSA-NCAM+CD24+
nephron precursor cells.
Polysialylation of neural cell adhesion molecule (PSA-NCAM) modulates cell-
cell homophilic binding and signalling during brain development (83) In the developing
neural system, NCAM polysialylation is required for cell proliferation and migration
(84, 85) and plays a role in neurogenesis, axonal pathfinding and nerve branching, since
negatively charged residue of NANA provide hydrodymamic space and induced anti-
adhesive effect on affected cells (86, 87). The NCAM+PSA-NCAM+CD24+ cells in CM
which also have proliferate activity (positive staining with Ki-67), and they represent
earlier renal progenitor cells for all future components of mature nephron. If we suppose
that PSA-NCAM molecules in kidneys play the same role as PSA-NCAM in neural
development, our morphological analysis of PSA-NCAM expression suggests that
polysialylated NCAM is required for further migration of renal progenitor and
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development of metanephros. Presence of Ki-67+ cells on PSA-NCAM+, but never on
NCAM+ cells only, also suggests that PSA-NCAM is correlated with cell proliferation.
Also, the expression of PSA-NCAM on morphologically younger nephron
precursors, followed by the expression of EpCAM, suggests that this post translational
modification of NCAM molecules could be a trigger for mesenchymal-epithelial
transformation (MET) in NCAM+ fetal nephron progenitors.
CD24 is a sialoglycoprotein, mainly known to be present on immature cells, as
well as on renal stem (progenitor) cell markers. Strong expression of CD24 and absence
of EpCAM expression in condense mesenchyme and pretubular aggregates, indicating
that CD24, similar like PSA-NCAM is an earlier marker of MET than CD326
(EpCAM), which is detected on nephron precursors in I stage of metanephron
differentiation, known as renal vesicle. Co-expression of CD24 with PSA-NCAM is
another proof that polysialylated NCAM is also a renal stem marker. CD24 may have an
important role in the commitment and transition of kidney mesenchymal cells to an
epithelial phenotype, upregulation of CD24 may also represent an important regulatory
step in the transition of a differentiated epithelium to a mesenchymal phenotype, as seen
in the model of epithelial injury and in specific forms of cancer (88). Although the role
of CD24 in renal development is currently unclear, expression of CD24 on cells in UB
tip and its co-expression with TRA-1-60 and E-cadherin on these structures suggest that
combination of these three surface markers may present epithelial renal progenitor pool
(TRA-1-60+E-CDH+CD24+ cells) in fetal tissue. Thus, we could conclude that in fetal
kidney tissue exist both mesenchymal and epithelial progenitor cell pools, and that
CD24 at one point of kidney development  was present in both, epithelial and
mesenchimal renal progenitor populations.
In fetal tissues TRA-1-60 is widely expressed on apical side of UB cells. The
TRA-1-60 epitope was identified as an isoform of the proteoglycan, podocalyxin and its
linked to dedifferentiation in embryonic carcinoma cells and one of a few antigens that
are widely used in human stem cell research as positive indicators of a true pluripotent
human stem cell (89-91). TRA-1-60 was also present in adult kidney and recent studies
showed its up-regulation in tubuo-interstitial diseases, and co-expression of TRA-1-60
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with Pax-2 and Ki-67 suggesting its role in reparation of distal tubules in diseased
kidney (92).
E-CDH as we mentioned was co-expressed with TRA-1-60 on UB cells, but it is
interesting to note that on mesenchymal nephron progenitors E-CDH was present on
CM derivates, start on the level of renal vesicle, in human fetal tissues. Similar
expression pattern of E-CDH have been already shown, indicating that E-CDH protein
is marker of MET (33). Interestingly E-CDH similar like CD24 was expressed on both
renal progenitor population pools.
Polysialylation of NCAM molecules on nephron precursors may be the first
stage in MET, since looking from morphological aspect PSA-NCAM is not present on
structures before condensation of induced mesenchyme. Considering immunostaining
profile, polysialylation of NCAM molecules starts at first stage of metanephron
development, in CM, and it remains till S shaped body, the last step before formation of
mature fetal glomeruli. Absence of polysialylated modification in uninduced
mesenchymal cells in medulla and in nephrogenic interstitium and on the other side
PSA-NCAM expression at the beginning of nephron development, i.e. stage of CM
suggests that NCAM polysialylation is necessary for further nephron differentiation.
Considering that lack of PSA-NCAM expression in neonatal, normal adult and cRCC
tissue (44) indicates PSA-NCAM as a potential renal fetal/embryonic form of NCAM
molecule.
Characterization of new marker, W1C3 by imunohistochemisrty and double
immunofluorescence showed co-expression (Figure 10) and co-localization (Figure 11)
with NCAM, suggesting that W1C3 is a new clone for NCAM. Nevertheless, FACS
analysis on HEK-293 cell line showed four times lower expression of W1C3 (4.2%) in
contrast to NCAM (16.8%) in same population. Nevertheless CD56+ subset of
mesemchymal stem cells (MSCs) showed increased expression of W1C3 antigen (93).
However, knowing that HEK-293 line was not the best “model” for analyses of renal
progenitors, W1C3 should be further tested on HFK lines and for precised identification
of W1C3 protein mass spectrophotomerty is necessary. W5C4C5 is one more new
mesenchymal marker which was DIF tested in relation to NCAM expression. W5C4C5
antibody showed broad co-localization pattern with NCAM in fetal samples, while in
adult tissue it was completely negative, except in nerve where also had overlap with
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NCAM. These findings suggest that like W1C3, W5C4C5 could be potential new clone
for NCAM. And like in W1C3 cases its identification requires mass spectrophotomerty
testing/ screaning. In addition W8B2 antigen was also tested in relation to NCAM.
Screening of the mesenchymal stem cell antigen 1 (MSCA-1), specific antibody W8B2
on HEK-293 cells transfected with the full-length coding sequence of tissue non-
specific alkaline phosphatase TNAP showed specific reactivity with transfected but not
with parent cell line. Show that MSCA-1 is identical to TNAP, an ectoenzyme known to
be expressed at high levels in liver, bone, and kidney as well as in embryonic stem (ES)
cells (94). DIF analyses did not showed any co-expression of W8B2 with NCAM in
fetal tissues. Thus, MSCA-1 was not detected on NCAM+ mesenchymal cells.
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5.2. Discussion considering NCAM expression in renal tumors and cell lines
Renal epithelial tumors comprise a heterogeneous group of tumors. Renal cell
carcinoma (RCC) has different histologic origin, metastatic potential, and clinical
outcomes; typically does not proliferate rapidly nor does it invade the surrounding
tissues, but it does metastasize. According to the classification in 2002 RCCs have five
subtype classifications, i.e., clear cell RCC, papillary RCC, chromophobe RCC,
collecting duct carcinomas, and unclassified RCC. This classification reflects the
location within the nephron from which the tumors originate. Epithelial cells of the
proximal part of the renal tubule give rise to clear cell and papillary RCC, while the
collecting tubule of the nephron gives rise to chromophobe RCC and collecting duct
carcinomas (95). RCC represents 80% of renal tumors in adults and is characterized by
lack of early warning signs, by frequent metastasis, and by resistance to currently used
treatments (95, 96). Cancer cells are characterized by indefinite proliferation,
invasiveness and metastases. These characteristics are usually related to one another.
Namely, cancer cells that proliferate rapidly tend to invade and metastasize. Therefore,
identification of molecular markers of tumor aggressiveness is urgently needed. In a
variety of human malignancies, tumor progression is associated with changes in cell
adhesion molecule (CAM) expression (97).
Significant number of studies revealed that not only that NCAM is essential
during neural and widely expressed in renal development, NCAM molecule also have
major role in initiation and regulation of NCAM mediated tumorigenesis in various
tissues. Thus, it has been known that NCAM is expressed in myeloid leukemia (35).
Also, immunohistology studies indicated NCAM as marker of neuroendocrine and
neuroectodermal tumors, as well as differential-diagnostic and prognostic marker of
multiple myeloma (36, 39). In renal cell carcinoma NCAM was first time described in
2003. In this study NCAM expression was detected in subgroup of aggressive cRCCs.
In particular, NCAM expression correlated strongly with the occurrence of metastases
in the CNS and adrenal gland, while survival of patients with NCAM-expressing RCCs
was lower than the survival of other patients (44). Much more recently study from 2012
also investigated NCAM expression on RCC. Results obtained in this study also
indicated that aggressive RCC behavior is related to NCAM expression. Nevertheless,
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this study pointed that NCAM expression is not characteristic for any particular RCC
subtype, thus NCAM is not useful marker for differential diagnostic of RCC (58).
In this thesis, we described for the first time co-expression of FGFR1 and
NCAM in different renal tumors. Co-expression of these two markers was analyzed by
immunohistochemistry in cRCC, pRCC and chRCC, in collecting duct carcinoma,
oncocytomas and in few other malignant and benign renal neoplasms. Co-expression of
both molecules was detected in the majority of studied renal tumors and moreover, co-
localization of these molecules on the same renal tumor cells was revealed by triple
immunofluorescent technique.
First functional interaction between FGFR1 and NCAM has been reported in
neurons (27). Thereafter, interplay between these two molecules in different non-neural
cells was reported, indicating that interaction of NCAM with FGFR results in
stimulation of FGFR signaling in various cell types (29, 98). It has been shown that
NCAM-mediated activation of FGFR leads to different cellular responses (99). Recent
publication on experimental cell cultures showed that NCAM-dependent FGFR
signaling promotes cell migration and invasion in epithelial ovarian carcinoma (60). The
mechanism of FGFR1 activation by NCAM is not well clarified. In particular, FGFR
membrane-proximal Ig3 module is known to bind to NCAM membrane-proximal Fn3
module (100). Also further analysis showed that FGFR Ig2 module is involved in direct
binding to the F3 (1-2) domains of NCAM and that Ig2 module has two binding sites for
NCAM (67). Several speculative models for molecular mechanisms of NCAM interplay
with FGFR1 were formulated based on this data (67,100).
Immunofluorescent technique was used to determine whether NCAM and
FGFR1 were present on same tumor cells. Thus, co-localization of NCAM and FGFR1
on the same renal tumor cells detected by triple staining could indicate that functional
interplay between NCAM and FGFR1 could occur in renal tumor tissues. Nevertheless,
semi-quantitative analysis of triple immunofluorescence showed that number of
FGFR1+/NCAM+ cells was increased with nuclear grade in cRCC and pRCC suggesting
that NCAM/FGFR1 interaction may be related and leads to aggressive behavior of these
tumors.
Staining pattern of NCAM expression was usually similar to the FGFR1 in
different RCC types. Lower grade RCC (I-II) had uniformly membranous expression of
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NCAM and FGFR1. Thus, we could say that membranous expression of both molecules
in lower grade RCCs could fit to “Kochoyan’s model” (67) suggesting that when
NCAM is not involved in cell adhesion between two neighboring cells, molecules are
uniformly spread on cell membrane, and FGFR molecules do not bind significantly to
NCAM. In these cases FGFR and NCAM molecules do not interact with each other,
suggesting that this model could be the key for low aggressive potential of these RCC.
Our results are somehow in concordance with recently obtained data based on human
ovarian carcinoma cell lines. In this study, ovarian carcinoma cell lines which
prominently express FGFRs were transfected with NCAM without Fn3 module
(NCAM-ΔF2). In vitro experiments showed that cells with NCAM-ΔF2 failed to
promote cell migration and invasion (60), suggesting that physical interaction between
FGFR1 and NCAM is required for aggressive tumor behavior. Also, same cell line in
mice formed tumors with smooth margins within the ovary, indicating that absence of
NCAM/FGFR interaction is responsible for poorly invasive potential of developed
tumor (60).
However, cRCC with higher NG (III-IV) and all pRCC (NG I-IV) in addition to
membranous had cytoplasmatic expression of both markers, while in chRCC
membranous and cytoplasmatic expression of FGFR1 was followed by weak mainly
cytoplasmatic NCAM expression. Interestingly, triple immunofluorescent technique in
RCC with high nuclear grade showed aggregated colocalized expression on cell
membrane of both molecules (Figure 28G-O). Thus, we found that expression of
FGFR1 and NCAM in tumor cells with higher nuclear grade leads to accumulation of
both molecules in cytoplasm and on membrane. Previous data show that when NCAM
is involved in cell-cell adhesion, NCAMs may aggregate/accumulate themselves
forming cis-dimers. These dimers via trans-homophilic bindings mediated cell-cell
adhesion making so-called “zipper” formations (13), presumed aggregation of NCAMs
lead to subsequent aggregation of FGFR molecules (67). Thus, Kochoyan et al proposed
a second model of NCAM/FGFR interaction: FGFR is expected to bind to and becomes
activated by NCAMs only when NCAM is clustered through a trans-homophilic
binding mechanism (67). It might be that this model could be applied to RCCs with high
nuclear grade, suggesting that aggregations of NCAM and FGFR1 on cell membrane
could activate NCAM/FGFR1 interplay which is then responsible for migration and
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invasive potential of these RCCs. Study on ovarian carcinoma mentioned above (60),
also pointed to crucial role of NCAM/FGFR interaction in aggressive tumor behavior.
Same cell lines were now transfected with full-length NCAM. Thus, cells which now
had Fn3 domain which is necessary for FGFR binding to NCAM showed migrations
and invasion of tumor cells in vitro and in vivo experiments (60), conforming the role of
NCAM/FGFR interaction in aggressive tumor behavior.
Results considering oncocytoma and metanephric adenoma, showed exclusively
cytoplasmatic co-localization of FGFR1 and NCAM. Since in both benign renal tumors
no membranous staining was detected, it seems that membranous expression is crucial
event for NCAM and FGFR1 interplay leading to tumor invasiveness while the lack of
NCAM/FGFR1 membranous expression is characteristic of renal benign tumors. In the
present study NCAM expression was detected in less number of RCC in comparison to
FGFR1. Expression of NCAM in renal tumors was also evaluated previously (41, 44).
Daniel et al detected membranous NCAM expression in cRCC only, and no staining in
pRCC and chRCC. They claim that NCAM expressing tumors behave aggressively and
metastasize preferentially to NCAM-expressing organs like CNS and adrenal gland
(44). Other, recently published data on NCAM expression in RCC, revealed
cytoplasmatic NCAM staining not only in cRCC but also in pRCC and chRCC, and
they did not find any association between NCAM expression and histological RCC
type, nuclear grade or stage (41). It remains unclear, why cited studies (41, 44) had
presented different staining pattern knowing that in both studies monoclonal antibody
for NCAM (CD56, Novocastra) which recognized external domain of NCAM molecule
had been used. On the other hand, in our study we revealed both staining patterns,
membranous and cytoplasmatic, using monoclonal NCAM antibody specific for
external (Fn3) domain. Lower grade tumors (I and II) cRCC and mcRCC had
membranous, while high grade cRCC, all pRCC, chRCC in addition to membranous
had also cytoplasmatic pattern. Thus, switch from NCAM negative to NCAM positive
RCC could be a crucial event for tumor aggressiveness and invasiveness, as it was
shown in the experiments by Lehembre et al (99), which clarified the importance of
NCAM expression for epithelial mesenchymal transition in the development and
progression of epithelial tumors.
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NCAM expression was detected by RT-PCR and immunostaining. NCAM-140
was present in all analyzed malignant and benign renal neoplasms. NCAM-140 plays
role in growth cones and axon shafts of developing neurons and modulates cell
adhesion, neuron growth and cell motility (101). Recent study showed that NCAM-140,
which has transmembrane domain, was expressed on various human malignancies,
inducing antiapoptotic/proliferative pathways and specifically phosphorylated calcium-
dependent kinases that are relevant for tumorigenesis (41). However, NCAM-120,
which does not have transmembrane domain, was present only in chRCC, oncocytoma
and metanephric adenoma. Functions of these two isoforms still have not been cleared
up in renal neoplasms and remain to be further investigated.
FGFR1 was present in great number of all analyzed renal neoplasms. Actually,
FGFR1 was present in high percentage of RCC, corresponding to recently published
data which showed expression of FGFR1 in 98% of primary RCC (102). Interestingly,
FGFR1 regulates different processes in invasive and non-invasive urothelial carcinomas
in cell culture experiments. FGFR1 expression in non-invasive urothelial carcinoma
promotes proliferation and survival, while in invasive urothelial carcinoma FGFR1
mediates invasion (103). We clearly revealed by imunohistochemistry and by precise
immunofluorescent technique on cryostat sections variable FGFR1 expressions on
different cell compartments: membranous in lower grade mcRCC and cRCC (NG I-II);
cytoplasmatic in addition to membranous in higher grade cRCC (NG III-IV), and in all
pRCC and chRCC; cytoplasmatic in all oncocytomas. Thus, variable FGFR1 expression
on various renal tumors could indicate different role of FGFR1 signaling in these
tumors.
Our results showed that most of analyzed renal tumors co-expressed NCAM and
FGFR1 and moreover co-localization of both markers on same tumor cell. Co-
expression of NCAM and FGFR1 is not related to histological type, origin, size, stage
and nuclear grade. Localization of NCAM and FGFR1 expression in different cell
compartments in various renal tumors suggests that NCAM/FGFR1 interaction possibly
has multipurpose and different function in tumor oncogenesis in kidney.
FACS analyses on tested tumor cell lines, CRL-1932 and TW33, showed very
interesting pattern of NCAM expression. Namely, low density cell cultures (CRL-1932)
were almost negative for NCAM expression and they showed only one cell population
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of alive cells. On the other hand, high density cultures (over 70%) had 2 populations of
cells. In these cultures smaller population strongly expressed NCAM (CRl-1932 –
57.67%), while bigger cell population had very weak NCAM expression. On the other
hand TW33 cell lines in both group (low and high density) had only one cell
population) and expression around 40%. Previously study on RCC cell lines also
showed diffuse NCAM expression on 6 different RCC cell lines (58). Thus, in
overcrowded cultures RCC cell lines could have two different cell phenotypes. These
finding suggest that cells will used NCAM for cell-cell assembling only when they are
“overcrowded”.
In addition, aquaporin 1 (AQP1) expression was correlated to NCAM in renal
neoplasm. AQP1, a water channel and regulator of endothelial cell migration is
expressed in different epithelial tissues, on endothelium and in some urinary tract
neoplasms. It is also considered as a differentiation marker for proximal renal tubular
cells, from which clear cell and papillary renal cell carcinoma originate. In the normal
kidney, AQP1 is only expressed in epithelial cells of proximal tubules and in the
descending limb of Henle, but not in other nephron segments, collecting ducts or
urothelial cells, whereas aquaporin-2 is selectively expressed in collecting ducts (104).
Recently investigation showed that beside function as water-transporting
proteins AQP1 regulates the expression of β-catenin, probably by maintaining the post-
translational level of β-catenin, further they demonstrated that AQP1 exerts its
migration enhancer function through modulating the expression of FAK. Thus, true
FAK pathway AQP1 promote MSCs migration. The systemic administration of AQP1-
MSCs into a rat fracture model showed that significantly more AQP1-MSCs migrated to
the fracture site, suggesting the potential therapeutic use of genetically modified AQP1-
MSCs in cell therapy applications (105).
In this thesis, AQP1 expression was seen in the majority of all cRCC and pRCC.
No significant difference was found comparing type 1 and type 2 pRCC carcinomas. All
oncocytomas were completely negative. Chromophobe renal cell carcinomas and
collecting duct carcinomas were negative. Interestingly in cRCC only rare tumor cells
had co-localization of NCAM and AQP1, while in pRCC NCAM+ tumor cells were
AQP1 negative and opposite. Fetal tissue in early gestation weeks does not express
AQP1 in nephron progenitor cells (data not shown). Therefore, AQP1 shows RCC
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subtype-specific expression and could be useful diagnostic marker for cRCC and pRCC
carcinomas. Immunohistochemistry study on 202 paraffin embedded RCC samples
showed that AQP1 expression decreased significantly in higher grades of cRCC
carcinomas, compared to lower grades of this tumor group. This was seen in clear cell
renal cell carcinomas but not in papillary renal cell carcinomas. Thus, AQP1 is reliable
markers for clear cell renal cell carcinomas of lower grades but not for higher grades,
(106). Still, absence of NCAM and APQ1 co-expression suggests that NCAM+ and
AQP1+ RCC cells belong to various cancer cell niches.
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5.3. Discussion considering adult tissue (normal and tissue with interstitial fibrosis)
The kidney derived, as it was note in introduction in interaction between UB and MM
cells. Thus these two progenitor cells pools will differentiate into more than 26 different
cell types in the adult kidney. MM cells widely expressed NCAM during kidney
development, but this expression is restricted to feotal and early postnatal stage (50).
While on adult normal tissue NCAM expression is reserve for nerve and rare single
interstitial cells (40). It has been widely accepted that, in contrast to other human
organs, normal renal tissue contains a few fibroblasts (62) and some other interstitial
cells, such as scarce NCAM+ cells with dendritic morphology, considered as renal
progenitor cells (40). However, the contribution of NCAM+ interstitial cells, as well as
their immunomorphological characteristics has not been fully elucidated.
Renal fibrosis, whether the origin is inflammatory or immunological,
obstructive, metabolic or systemic is inevitably progresses to end-stage renal disease.
Glomerular inflammation, mesangial expansion and sclerosis have all been considered
important factors in the development of chronic kidney disease (CKD). In the majority
of patients with CKD, however, the progression of renal insufficiency is most closely
correlated to the degree of tubular atrophy and interstitial fibrosis. Fibrosis can be
considered aberrant wound healing, in which there is progression rather than resolution
of scarring following injury and fibroblasts are central to this process. Fibroblasts have
distinct phenotypes depending on the disease and site from which they are isolated.
Fibroblasts in the interstitium of kidneys with chronic progressive disease take on a
contractile myofibroblastic phenotype and are responsible for the formation of the
fibrillar collagen-rich extracellular matrix (ECM) that fills the interstitium leading to
nephron loss and declining kidney function. The presence of myofibroblasts is,
therefore, recognized as a predictor of fibrotic progression in both experimental models
and human renal diseases (62). Renal interstitium of fibrotic kidney contains a large
morphological heterogeneity of cells, mainly fibroblasts and myofibroblasts (66, 107).
In this thesis, NCAM+ cells were confirmed in less than a half of the analyzed
human biopsy specimens, where they were usually associated with interstitial fibrosis.
These results are in correlation to previously findings by Markovic-Lipkovski et al (40).
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Increase of NCAM+ cells was found in incipient renal fibrosis, usually in the areas of
peritubular slight fibrosis without tubular atrophy, whereas in the majority of cases in
advanced fibrosis they were almost absent. Previous study (108) has also revealed
increased density of NCAM+ interstitial cells in early phase of repairing process after
ischemic tubular injury in rats, with rapid decline few days after injury. Nevertheless, it
is possible that rare NCAM+ cells which are increased in initial phase of fibrosis
represent residue of previously mentioned NCAM+EpCAM- progeniror cells in fetal
tissues, suggested as stromal precursors (33). Altogether, it could implicate a regulatory
role of NCAM+ cells in the initial phase after injury, suggesting that these interstitial
cells exhibit transient phenotype. Thus, immunophenotyping of NCAM+ cells could
help us to clarify their origin, putative role and fate. Therefore, we further investigated
whether NCAM+ renal interstitial cells express other molecular markers relevant for
fibrosis, such as FGFR1, CDH9 and α5β1 integrin.
NCAM+ renal interstitial cells, like renal fibroblasts, display a large degree of
heterogeneity, even in normal human adult kidneys. In fact, in some renal tissues, it was
impossible to find interstitial cells coexpressing NCAM with FRGR1, or α5β1 integrin,
while in others NCAM+/FGFR1+ or NCAM+/α5β1+ integrin cells were detectable.
FGFR1 receptor is involved in initial activation and proliferation of fibroblasts that are
responsible for collagen production (98), and could be directly activated by interaction
with NCAM molecule which additionally promotes FGFR1 recycling, resulting in
sustained FGFR1 signaling that is important for fibroblast migration (98, 100).
However, NCAMs which mediate cell-cell adhesions, by forming NCAM trans-
homophilic binding via “zipper”-like structures, have been expected to bind and activate
FGFR1 (109, 110). This could be the underlying mechanism of the strict and abundant
overlapping between NCAM and FGFR1 molecules observed in the areas with incipient
fibrosis in some cases in our study. However, the dendritic morphology of NCAM
positive interstitial cells allows them to communicate easily with each other, suggesting
that strict increase of NCAM expressing cells is not necessary for FGFR1/NCAM
interplay. Especially if we know that in neural cells NCAM/FGFR interaction can be
modified by other molecules present in cell or in extracelular matrix. Thus, previously
noted study (100) showed by nuclear magnetic resonance that adenosine triphosphate
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(ATP) binding site to NCAM overlaps with FGFR, so ATP can inhibit NCAM/FGFR
interaction.
All major NCAM isoforms can cooperate with FGFR1 (111), and after applying
PCR we have not detected any difference concerning major NCAM isoforms on normal
and fibrotic renal tissues. Receptor α5β1 integrin, present on mesenchymal derived cells
(112), is known to be involved in extracellular matrix assembly, cell adhesion,
migration, proliferation and differentiation (70, 99, 113, 114). Since it has been
significantly increased in fibrotic kidneys (40, 113), we were encouraged to search for
renal interstitial cells co-expressing NCAM and α5β1 integrin. Considering that co-
expression of NCAM and β1 integrin is essential for mesenchymal cell motility (99,
114), NCAM+/α5β1 integrin+ interstitial cells could also represent migratory cells
easily involved in the renal cell cross-talk. In neural cells NCAM regulates important
aspects of integrin-dependent cell migration, axonal/dendritic outgrowth, and synaptic
targeting. In brief NCAM interact functionally with integrins and activate convergent
signaling pathways leading to ERK MAP kinase. NCAM induces recruitment of
tyrosine kinase Fyn to its intracellular domain, which turn activates of FAK, ERK, and
the transcription factor cAMP response element binding protein (CREB), which
stimulates neurite outgrowth. FAK is a key intracellular regulator of migration in
nonneuronal cells, acting by increasing turnover of focal adhesive contacts at the cell’s
leading edge (115). Furthermore, since α5β1 integrin expressed by fibroblasts promotes
acquisition of myofibroblastic phenotype (113), it could probably implicate the same
fate of NCAM+/α5β1 integrin+ cells, suggesting that this phenotype might be transient.
The origin of NCAM+ renal interstitial cells remains unclear. Very likely, they
represent resident cells which persist after the embrionic kidney development from
metanephric nephros that widely expresses NCAM (33). On the other hand, abundant
expression of α5β1 integrin in cultured bone marrow progenitor cells (116), as well as
expression of α5β1 integrin in addition to CD34 on some NCAM+ interstitial cells (40),
could further support our previous idea that the subpopulation of NCAM+ could
originate from bone marrow and could be renal progenitor cells. It is tempting to
speculate that NCAM positive renal interstitial cells, under particular pathological
conditions, could represent transdifferentiated cells derived from tubular epithelium,
since NCAM could be re-expressed in these cells after injury (33, 117) and because the
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expression of α5β1 integrin could be acquired de novo in migrating epithelial cells
during wound healing (63, 118).
In addition, in this thesis, for the he first time rare NCAM+/CDH9+ interstitial
cells were detected. CDH9 was first time described in brain and together with cadherin-
7 and -10 belong to type-II classic cadherins in humans. Together with all other type II
class cadherins, CDH9 interact with catenins and it is involved in cadherin-mediated
mechanisms of development, morphogenesis and cell-cell interactions/adhesion (119).
Initial RT-PCR analyses in renal tissue had revealed that the mRNA for CDH9 was
transcribed in the adult human kidney and that CDH9 play a role in cell-cell interaction
as shown by a cell aggregation assay (77). Further, all RCC cell lines tested were
negative for CDH9 on the mRNA and protein levels and in RCC tissue CDH9 was
expressed in stromal, but nor on tumor cells. These findings indicated that CDH9 is
exclusively expressed by renal fibroblasts (77). Thus, we could suggest that
NCAM+CDH9+ interstitial cells are one type of renal fibroblast involved in tissue
regeneration and wound healing.
Furthermore, in this study also for the first time NCAM+/PSA-NCAM+
interstitial cells were detected in incipient interstitial fibrosis. We have seen that in fetal
human tissues polysialilation of NCAM molecules is necessary for proper kidney
development. Also, in neural development, interactions between heavily polysialylated
NCAM molecules, due to a weaker one dimensional zipper formation, favors NCAM
signaling. Thus, expression of PSA by NCAM may function as a ‘switch’, regulating
whether NCAM is involved in adhesion or signaling. This notion is grounded by the
facts that removal of PSA inhibits NCAM-stimulated neurite outgrowth (100).
Interestingly expression of PSA-NCAM during embryonic period and absence of typical
dendritic morphology in NCAM+/PSA-NCAM+ cells in initial phase of interstitial
fibrosis suggest that these cells may be rump from nephron precursors.
One more, very interesting result obtained in this work was detection of new
marker W8B2 in initial interstitial fibrosis. W8B2 was also detected in some tubular
cells in fetal tissues, but it did not co-localized with NCAM. In contrary in interstitial
fibrosis rare NCAM+/W8B2+ cells were detected. W8B2, mesenchymal marker, is
identical to tissue non-specific alkaline phosphatase (TNAP), enzyme which probably
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had function in matrix mineralization (94). Rare NCAM+/W8B2+ cells are one more
type of interstitial cells and they should be father investigated.
To summarized, detection of five different types of NCAM+ interstitial cells is one
more conformation of huge heterogeneity of NCAM+ interstitial cell. Co-expression of
NCAM with FGFR1, integrin α5β1, CDH9 and PSA indicated NCAM role in different
types of cell signaling which are related to cell proliferation, migration, differentiation.
Thus, NCAM+ interstitial cells could be involver in repairing process after injury.
Recently, Harari-Steinberg et al showed that HFK cell lines (1 x 105 – 5 x 105) cultured
in SFM and which expressed NCAM+ after performed grafting experiments on the
chorio-allantoic membrane (CAM) of a chick embryo succeed to form tubular structures
in 4/6 grafts; while the same numbers of NCAM negative cells completely failed to
generate similar structures (82). Tubular structures obtained on this way, were tested by
immunohistochemistry for tubular epithelial markers. Thus, staining conformed that
NCAM+ progenitors undergo MET and form tubular epithelial cells, demonstrates their
enriched and broad intrinsic differentiation capacity that NCAM negative progenitor
lack. The same study also revealed that in vitro cultured NCAM+ human nephron
progenitor cells (hNPCs) improve the outcome of chronic renal injury (82).
Further studies are necessary to explain why NCAM expression is increased
only in the initial phase of repairing process and to clarify molecular mechanisms that
determine whether physiological repair or pathologic fibrosis would occur. They have to
highlight the manifold and diverse role of heterogeneous morphology of NCAM
positive renal interstitial cells, revealed in this thesis, as well as their influence on renal
fibrosis which probably depends on other molecular markers that NCAM positive cells
could share.
102
6. Conclusions
1. Appling RT-PCR, three major NCAM isoforms mRNA transcripts (120, 140, 180
kDa) have been detected both in healthy fetal and adult renal tissues, as well as in adult
kidneys with interstitial fibrosis. However, adult renal cell tumours expressed only 120
and 140 kDa isoforms.
2. PSA-NCAM was presented on nephron progenitors, starting from CM up to S shaped
body, whereby it was not detected in neonatal and adult healthy tissues, suggesting that
post-translational modification with polysialic acid was characteristic of fetal renal
tissues and PSA-NCAM could be an embryonic NCAM form of renal tissue.
3. Polysialylation of NCAM molecules on mesenchymal nephron precursors may be the
first sign of MET initiation, since from morphological aspect, PSA is necessary for
condensation of induced mesenchyme.
4. Compared to widespread NCAM expression on metanephric mesenchyme cells,
either those induced or uninduced by uretheric bud, PSA-NCAM was detected only on
mesenchymal nephron precursors, cells induced to form further mature nephron
formations. It could suggest that NCAM polysialylation was important for normal
nephron differentiation, since mesenchymal cells in medulla and in interstitium did not
exhibit NCAM polysialylation.
5. New cell surface markers W1C3 and W5C4C5 stained same cells as NCAM in fetal
and adult healthy renal tissues, implicating that W1C3 and W5C4C5 detect the same
molecules in tissues as NCAM.
6. NCAM was expressed in majority of analyzed RCC. NCAM+ tumor cells in RCC
were also FGFR1+. Co-expression of NCAM and FGFR1 is not related to histological
type, origin, size, stage and nuclear grade.
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7. Different patterns of NCAM and FGFR1 co-localizations within tumor cell
compartments of various tumor types could suggest diverse roles that might have an
influence on biological tumor behavior.
8. NCAM+ renal interstitial cells are significantly increased in the initial phase of renal
interstitial fibrosis. They display a morphological heterogeneity concerning co-
expression of FGFR1, α5β1 integrin and other molecules relevant for renal interstitial
fibrosis, and could be responsible for the regulation of healing process in the kidney.
However, their precise roles have remained to be further clarified.
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